EP4185340A1 - Nanoparticles, nanofunctionalised substrate and device with antiviral and/or antibacterial and/or antifungal photocatalytic activity - Google Patents
Nanoparticles, nanofunctionalised substrate and device with antiviral and/or antibacterial and/or antifungal photocatalytic activityInfo
- Publication number
- EP4185340A1 EP4185340A1 EP21755821.2A EP21755821A EP4185340A1 EP 4185340 A1 EP4185340 A1 EP 4185340A1 EP 21755821 A EP21755821 A EP 21755821A EP 4185340 A1 EP4185340 A1 EP 4185340A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nanoparticles
- substrate
- virus
- nanofunctionalised
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 282
- 239000000758 substrate Substances 0.000 title claims abstract description 238
- 230000000844 anti-bacterial effect Effects 0.000 title description 34
- 230000001699 photocatalysis Effects 0.000 title description 26
- 230000000840 anti-viral effect Effects 0.000 title description 10
- 230000000843 anti-fungal effect Effects 0.000 title description 6
- 229940121375 antifungal agent Drugs 0.000 title description 3
- 241000700605 Viruses Species 0.000 claims abstract description 124
- 241000894006 Bacteria Species 0.000 claims abstract description 116
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 108
- 241000233866 Fungi Species 0.000 claims abstract description 89
- 230000002147 killing effect Effects 0.000 claims abstract description 79
- 230000005855 radiation Effects 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 42
- 241000711443 Bovine coronavirus Species 0.000 claims description 41
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 241001480037 Microsporum Species 0.000 claims description 26
- 239000012530 fluid Substances 0.000 claims description 25
- 241000228212 Aspergillus Species 0.000 claims description 23
- 241000223682 Exophiala Species 0.000 claims description 23
- 241000295644 Staphylococcaceae Species 0.000 claims description 23
- 241001112741 Bacillaceae Species 0.000 claims description 20
- 241001248433 Campylobacteraceae Species 0.000 claims description 20
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 20
- 241000222290 Cladosporium Species 0.000 claims description 20
- 241001430149 Clostridiaceae Species 0.000 claims description 20
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 20
- 241000588921 Enterobacteriaceae Species 0.000 claims description 20
- 241001609975 Enterococcaceae Species 0.000 claims description 20
- 241000223218 Fusarium Species 0.000 claims description 20
- 241000589246 Legionellaceae Species 0.000 claims description 20
- 241000589901 Leptospiraceae Species 0.000 claims description 20
- 241000192017 Micrococcaceae Species 0.000 claims description 20
- 241000589289 Moraxellaceae Species 0.000 claims description 20
- 241000235395 Mucor Species 0.000 claims description 20
- 241000186360 Mycobacteriaceae Species 0.000 claims description 20
- 241000228143 Penicillium Species 0.000 claims description 20
- 241000947836 Pseudomonadaceae Species 0.000 claims description 20
- 241000235527 Rhizopus Species 0.000 claims description 20
- 241000589971 Spirochaetaceae Species 0.000 claims description 20
- 241000194018 Streptococcaceae Species 0.000 claims description 20
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims description 19
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 16
- 241001678559 COVID-19 virus Species 0.000 claims description 15
- 241000315672 SARS coronavirus Species 0.000 claims description 14
- 208000006454 hepatitis Diseases 0.000 claims description 14
- 231100000283 hepatitis Toxicity 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 12
- -1 polyethylene terephthalate Polymers 0.000 claims description 12
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 11
- 241000711573 Coronaviridae Species 0.000 claims description 9
- 241000191967 Staphylococcus aureus Species 0.000 claims description 9
- 229910010293 ceramic material Inorganic materials 0.000 claims description 9
- 229910052878 cordierite Inorganic materials 0.000 claims description 8
- JSKIRARMQDRGJZ-UHFFFAOYSA-N dimagnesium dioxido-bis[(1-oxido-3-oxo-2,4,6,8,9-pentaoxa-1,3-disila-5,7-dialuminabicyclo[3.3.1]nonan-7-yl)oxy]silane Chemical compound [Mg++].[Mg++].[O-][Si]([O-])(O[Al]1O[Al]2O[Si](=O)O[Si]([O-])(O1)O2)O[Al]1O[Al]2O[Si](=O)O[Si]([O-])(O1)O2 JSKIRARMQDRGJZ-UHFFFAOYSA-N 0.000 claims description 8
- 241000589886 Treponema Species 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 7
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 7
- 241000711950 Filoviridae Species 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 241001115402 Ebolavirus Species 0.000 claims description 4
- 241000194032 Enterococcus faecalis Species 0.000 claims description 4
- 241000588722 Escherichia Species 0.000 claims description 4
- 241000712464 Orthomyxoviridae Species 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 241000700625 Poxviridae Species 0.000 claims description 4
- 241000700647 Variola virus Species 0.000 claims description 4
- 229920002877 acrylic styrene acrylonitrile Polymers 0.000 claims description 4
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 claims description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 4
- KZHJGOXRZJKJNY-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Si]=O.O=[Al]O[Al]=O.O=[Al]O[Al]=O.O=[Al]O[Al]=O KZHJGOXRZJKJNY-UHFFFAOYSA-N 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 229910052863 mullite Inorganic materials 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 239000004800 polyvinyl chloride Substances 0.000 claims description 4
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 4
- 241000701242 Adenoviridae Species 0.000 claims description 3
- 241001339993 Anelloviridae Species 0.000 claims description 3
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 3
- 241001277988 Aspergillus sydowii Species 0.000 claims description 3
- 241001533362 Astroviridae Species 0.000 claims description 3
- 241000714198 Caliciviridae Species 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000144583 Candida dubliniensis Species 0.000 claims description 3
- 241000222173 Candida parapsilosis Species 0.000 claims description 3
- 241000222178 Candida tropicalis Species 0.000 claims description 3
- 241001149955 Cladosporium cladosporioides Species 0.000 claims description 3
- 241001149956 Cladosporium herbarum Species 0.000 claims description 3
- 241001508813 Clavispora lusitaniae Species 0.000 claims description 3
- 241000193163 Clostridioides difficile Species 0.000 claims description 3
- 241000193155 Clostridium botulinum Species 0.000 claims description 3
- 241000193468 Clostridium perfringens Species 0.000 claims description 3
- 241000193449 Clostridium tetani Species 0.000 claims description 3
- 201000007336 Cryptococcosis Diseases 0.000 claims description 3
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 3
- 241000588914 Enterobacter Species 0.000 claims description 3
- 241000248325 Exophiala dermatitidis Species 0.000 claims description 3
- 241001662137 Exophiala hongkongensis Species 0.000 claims description 3
- 241000223664 Exophiala jeanselmei Species 0.000 claims description 3
- 241000650709 Exophiala phaeomuriformis Species 0.000 claims description 3
- 241001669606 Exophiala pisciphila Species 0.000 claims description 3
- 241000223221 Fusarium oxysporum Species 0.000 claims description 3
- 241001500351 Influenzavirus A Species 0.000 claims description 3
- 241001500350 Influenzavirus B Species 0.000 claims description 3
- 241000588748 Klebsiella Species 0.000 claims description 3
- 241001534216 Klebsiella granulomatis Species 0.000 claims description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 3
- 241000589242 Legionella pneumophila Species 0.000 claims description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 3
- 241001480000 Microsporum audouinii Species 0.000 claims description 3
- 241001299895 Microsporum ferrugineum Species 0.000 claims description 3
- 241000907556 Mucor hiemalis Species 0.000 claims description 3
- 241001467553 Mycobacterium africanum Species 0.000 claims description 3
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 claims description 3
- 241000186362 Mycobacterium leprae Species 0.000 claims description 3
- 241000187492 Mycobacterium marinum Species 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 241000187917 Mycobacterium ulcerans Species 0.000 claims description 3
- 241001443590 Naganishia albida Species 0.000 claims description 3
- 241000222051 Papiliotrema laurentii Species 0.000 claims description 3
- 241000228150 Penicillium chrysogenum Species 0.000 claims description 3
- 241001223091 Penicillium corylophilum Species 0.000 claims description 3
- 241000985530 Penicillium glabrum Species 0.000 claims description 3
- 241000709664 Picornaviridae Species 0.000 claims description 3
- 241000702247 Reoviridae Species 0.000 claims description 3
- 240000005384 Rhizopus oryzae Species 0.000 claims description 3
- 235000013752 Rhizopus oryzae Nutrition 0.000 claims description 3
- 241000235546 Rhizopus stolonifer Species 0.000 claims description 3
- 241001138501 Salmonella enterica Species 0.000 claims description 3
- 241000607768 Shigella Species 0.000 claims description 3
- 241000607764 Shigella dysenteriae Species 0.000 claims description 3
- 241000607762 Shigella flexneri Species 0.000 claims description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 3
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 3
- 241000194019 Streptococcus mutans Species 0.000 claims description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 241001523006 Talaromyces marneffei Species 0.000 claims description 3
- 241000589884 Treponema pallidum Species 0.000 claims description 3
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 claims description 3
- 241000645784 [Candida] auris Species 0.000 claims description 3
- 241000222126 [Candida] glabrata Species 0.000 claims description 3
- 108700010877 adenoviridae proteins Proteins 0.000 claims description 3
- 229940091771 aspergillus fumigatus Drugs 0.000 claims description 3
- 229940095731 candida albicans Drugs 0.000 claims description 3
- 208000032343 candida glabrata infection Diseases 0.000 claims description 3
- 229940055022 candida parapsilosis Drugs 0.000 claims description 3
- 239000011111 cardboard Substances 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 229940115932 legionella pneumophila Drugs 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229960003085 meticillin Drugs 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 239000011087 paperboard Substances 0.000 claims description 3
- 229940094461 penicillium glabrum Drugs 0.000 claims description 3
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 claims description 3
- 229940007046 shigella dysenteriae Drugs 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 239000004753 textile Substances 0.000 claims description 3
- 229920001634 Copolyester Polymers 0.000 claims description 2
- 208000037262 Hepatitis delta Diseases 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- QMRNDFMLWNAFQR-UHFFFAOYSA-N prop-2-enenitrile;prop-2-enoic acid;styrene Chemical compound C=CC#N.OC(=O)C=C.C=CC1=CC=CC=C1 QMRNDFMLWNAFQR-UHFFFAOYSA-N 0.000 claims description 2
- 241001515965 unidentified phage Species 0.000 claims description 2
- 241000724675 Hepatitis E virus Species 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000724709 Hepatitis delta virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 59
- 230000001678 irradiating effect Effects 0.000 abstract description 15
- 239000000725 suspension Substances 0.000 description 93
- 238000012360 testing method Methods 0.000 description 80
- 239000000843 powder Substances 0.000 description 53
- 238000000576 coating method Methods 0.000 description 35
- 239000011248 coating agent Substances 0.000 description 34
- 239000003795 chemical substances by application Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 230000001717 pathogenic effect Effects 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 230000003253 viricidal effect Effects 0.000 description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 230000008569 process Effects 0.000 description 19
- 239000003899 bactericide agent Substances 0.000 description 18
- 239000000417 fungicide Substances 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 18
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 17
- 239000010949 copper Substances 0.000 description 16
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 15
- 239000003960 organic solvent Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000002019 doping agent Substances 0.000 description 14
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 13
- 229910052802 copper Inorganic materials 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 12
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 230000000813 microbial effect Effects 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 10
- 238000002296 dynamic light scattering Methods 0.000 description 10
- 238000000227 grinding Methods 0.000 description 10
- 239000002054 inoculum Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 229910052709 silver Inorganic materials 0.000 description 10
- 239000004332 silver Substances 0.000 description 10
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 10
- 229910021653 sulphate ion Inorganic materials 0.000 description 10
- 239000004408 titanium dioxide Substances 0.000 description 10
- 239000012137 tryptone Substances 0.000 description 10
- 241001646716 Escherichia coli K-12 Species 0.000 description 9
- 239000011941 photocatalyst Substances 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 8
- 238000001354 calcination Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000010146 3D printing Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- 241000008904 Betacoronavirus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000013068 control sample Substances 0.000 description 6
- 238000001746 injection moulding Methods 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 239000011787 zinc oxide Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 5
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 150000001879 copper Chemical class 0.000 description 5
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- 238000003618 dip coating Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 238000007146 photocatalysis Methods 0.000 description 5
- 238000000518 rheometry Methods 0.000 description 5
- 229910001961 silver nitrate Inorganic materials 0.000 description 5
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical class [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 5
- 239000010936 titanium Substances 0.000 description 5
- 229910052719 titanium Inorganic materials 0.000 description 5
- 241000711467 Human coronavirus 229E Species 0.000 description 4
- 241000482741 Human coronavirus NL63 Species 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700629 Orthopoxvirus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000007607 die coating method Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000005670 electromagnetic radiation Effects 0.000 description 3
- 238000007756 gravure coating Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007759 kiss coating Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000007760 metering rod coating Methods 0.000 description 3
- 239000002114 nanocomposite Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004528 spin coating Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000010345 tape casting Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000004176 Alphacoronavirus Species 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000494545 Cordyline virus 2 Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-Histidine Natural products OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 239000004133 Sodium thiosulphate Substances 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000009500 colour coating Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000012855 volatile organic compound Substances 0.000 description 2
- QUVMSYUGOKEMPX-UHFFFAOYSA-N 2-methylpropan-1-olate;titanium(4+) Chemical compound [Ti+4].CC(C)C[O-].CC(C)C[O-].CC(C)C[O-].CC(C)C[O-] QUVMSYUGOKEMPX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241001339888 Alphatorquevirus Species 0.000 description 1
- 241001135163 Arcobacter Species 0.000 description 1
- 241001135164 Arcobacter butzleri Species 0.000 description 1
- 241001443586 Atadenovirus Species 0.000 description 1
- 241001058044 Avastrovirus Species 0.000 description 1
- 241000469174 Avastrovirus 1 Species 0.000 description 1
- 241000469177 Avastrovirus 2 Species 0.000 description 1
- 241000469176 Avastrovirus 3 Species 0.000 description 1
- 241000701802 Aviadenovirus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241001536371 Bacillus oleronius Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000008905 Betacoronavirus 1 Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000702221 Cystoviridae Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241001447154 Leptospira alexanderi Species 0.000 description 1
- 241000589927 Leptospira borgpetersenii Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 241001148628 Leptospira kirschneri Species 0.000 description 1
- 241000667106 Leptospira kmetyi Species 0.000 description 1
- 241001135196 Leptospira noguchii Species 0.000 description 1
- 241001135198 Leptospira santarosai Species 0.000 description 1
- 241001135200 Leptospira weilii Species 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000702318 Microviridae Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000701553 Myoviridae Species 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000702072 Podoviridae Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- 241001137861 Rotavirus B Species 0.000 description 1
- 241001506005 Rotavirus C Species 0.000 description 1
- 241000373026 Rotavirus D Species 0.000 description 1
- 241001076205 Rotavirus F Species 0.000 description 1
- 241001076206 Rotavirus G Species 0.000 description 1
- 241000502473 Rotavirus H Species 0.000 description 1
- 241000925532 Rotavirus I Species 0.000 description 1
- 241001394254 Rotavirus J Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000620568 Siadenovirus Species 0.000 description 1
- 241000702202 Siphoviridae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001147687 Staphylococcus auricularis Species 0.000 description 1
- 241001147736 Staphylococcus capitis Species 0.000 description 1
- 241001147695 Staphylococcus caprae Species 0.000 description 1
- 241001147698 Staphylococcus cohnii Species 0.000 description 1
- 241001134656 Staphylococcus lugdunensis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241001339866 Torque teno virus 1 Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- ZEIWWVGGEOHESL-UHFFFAOYSA-N methanol;titanium Chemical compound [Ti].OC.OC.OC.OC ZEIWWVGGEOHESL-UHFFFAOYSA-N 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QGLKJKCYBOYXKC-UHFFFAOYSA-N nonaoxidotritungsten Chemical compound O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 QGLKJKCYBOYXKC-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002897 organic nitrogen compounds Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 238000013033 photocatalytic degradation reaction Methods 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- HKJYVRJHDIPMQB-UHFFFAOYSA-N propan-1-olate;titanium(4+) Chemical group CCCO[Ti](OCCC)(OCCC)OCCC HKJYVRJHDIPMQB-UHFFFAOYSA-N 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Substances [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229910001930 tungsten oxide Inorganic materials 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/088—Radiation using a photocatalyst or photosensitiser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0076—Radiation using a photocatalyst or photosensitiser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/16—Disinfection, sterilisation or deodorisation of air using physical phenomena
- A61L9/18—Radiation
- A61L9/20—Ultraviolet radiation
- A61L9/205—Ultraviolet radiation using a photocatalyst or photosensitiser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/25—Rooms in buildings, passenger compartments
Definitions
- Nanoparticles, nanofunctionalised substrate and device with antiviral and/or antibacterial and/or antifungal photocatalytic activity are examples of nanoparticles, nanofunctionalised substrate and device with antiviral and/or antibacterial and/or antifungal photocatalytic activity.
- the present invention fits into the field of photocatalytic degradation for disinfection and/or sanitisation applications.
- the present invention relates to the use of nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight, a substrate nanofunctionalised with said nanoparticles and a device comprising said substrate for killing viruses and/or fungi and/or bacteria.
- T1O2-N nitrogen-doped T1O2
- the present invention also relates to a method for killing said virus and/or said fungi and/or said bacteria.
- Infectious diseases i.e. diseases caused by pathogenic agents that come into contact with an individual, still today represent one of the main causes of disability and/or death worldwide.
- viruses, fungi and bacteria which can be transmitted from person to person or from animals to people, represent a problem that is of increasing concern in today’s society.
- antibiotic-resistant bacteria the spread of antibiotic-resistant bacteria is particularly worrying, both in hospital settings, where ample use is often made of antibiotics and personnel/visitors (potential carriers of bacteria) and patients (often immunocompromised) are often in close contact, and, for example, in the context of livestock farming.
- antibiotics are often administered in massive amounts to animals, also healthy ones, in order to prevent infections that could impair their growth or cause diseases.
- antibiotic-resistant bacteria could develop which are potentially transmittable also to humans, for example, by ingestion of food products derived from the animals themselves.
- bacteria both of the species Escherichia coli and Staphylococcus aureus are often responsible for this phenomenon of resistance, and can have a role in transferring this resistance to humans precisely through food.
- bacteria both of the species Escherichia coli and Staphylococcus aureus are often responsible for this phenomenon of resistance, and can have a role in transferring this resistance to humans precisely through food.
- the concentration of a large number of people in increasingly crowded urban spaces and the increasing ease of international travel have greatly contributed to the spread of pathogenic agents over a short period and in different parts of the world.
- coronaviruses which have been responsible for various epidemics since 2002, caused by SARS-CoV-1 , MERS-CoV and, at present, SARS-CoV-2 (COVID-19), the causative agent of the most recent pandemic (2019-2020).
- SARS-CoV-2 also because of its high virulence and ability to cause high mortality, has become an unprecedented global public health emergency.
- Coronaviruses are enveloped positive-sense RNA viruses belonging to the family Coronaviridae and the order Nidovirales and are considered the largest positive- sense RNA viruses, with genomes ranging from 27 to 32 kb.
- CoVs are the cause of a variety of respiratory, gastrointestinal and central nervous system diseases both in humans and in animals, and are capable of adapting to new environments by mutation and recombination.
- the transmission of these viruses can occur through contact with or close proximity to an infected person, or through contact with infected objects or surfaces and subsequent transmission of the pathogenic agent through contact with the nose, mouth or eyes.
- pathogenic agents are in fact capable of surviving in the environment for hours or days (and in some cases for months), contaminating surfaces, medical equipment or environmental media such as water or air in general.
- transmission may also occur through asymptomatic individuals, thus making it extremely difficult to control the spread of the disease.
- Titanium dioxide-based photocatalysts show numerous advantages, including the modest cost, high availability, nontoxicity, chemical and thermal stability and high oxidative power of Ti02.
- UVA/UVB ultraviolet light
- the technical task at the basis of the present invention is to propose an optimised alternative to photocatalysts for killing viruses and/or fungi and/or bacteria, in particular by providing a photocatalyst that works with both UV light and visible light, as well as sunlight, and which has the same effectiveness as or a greater effectiveness than the photocatalysts known in the art and can be adapted to cover different substrates.
- the present invention enables the problems of the prior art to be solved through the use of a photocatalyst based on nitrogen-doped titanium dioxide (T1O2-N) nanoparticles with photocatalytic activity to kill viruses and/or fungi and/or bacteria, in a short time, without emissions of contaminants (as occurs, for example, in the case of ozone sanitisation devices) and which is active in both the UV and visible light spectra, thus overcoming the high costs and problems of accessibility tied to the use of UV lamps, such as, for example, the production of O3.
- T1O2-N nitrogen-doped titanium dioxide
- the present invention relates to the use of nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight, a substrate nanofunctionalised with said nanoparticles, a device comprising at least one substrate nanofunctionalised with said nanoparticles and at least one light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm, for killing a virus and/or fungi, said fungi being selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium and a combination thereof; and/or bacteria, said bacteria being selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae
- the present invention also relates to a method for killing said virus and/or said fungi and/or said bacteria, comprising the steps of:
- said virus is preferably selected in the group consisting of: Coronaviridae, Bacteriaofagi, Caliciviridae, Picornaviridae, Reoviridae, Adenoviridae, Astroviridae, Anelloviridae, Pramixoviridae, Poxviridae, Filoviridae, Orthomyxoviridae, hepatitis virus, and a combination thereof.
- said virus and/or said fungi and/or said bacteria are comprised within a fluid, preferably air and/or water and/or a body fluid, or are present on a surface, preferably adsorbed onto said surface.
- said T1O2-N nanoparticles comprise at least a brookite crystalline phase in an amount of 10 to 99 % by weight relative to the weight of the nanoparticles and a rutile crystalline phase in an amount of 25 to 90% by weight relative to the weight of the nanoparticles; more preferably, said T1O2-N nanoparticles further comprise an anatase crystalline phase in an amount of 1 to 10 % by weight or 25 to 90% by weight relative to the weight of the nanoparticles.
- said amount of the brookite crystalline phase means that said brookite crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes, such as, for example, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%,
- said amount of the rutile crystalline phase means that said rutile crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes, such as, for example, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%,
- said amount of the anatase crystalline phase means that said anatase crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes, such as, for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%,
- said PO2-N nanoparticles have a nitrogen doping content comprised between 1 and 5% by weight relative to the weight of the nanoparticles.
- said substrate is selected in the group consisting of: a substrate of ceramic, polymeric or textile material, nonwoven fabric, metal, glass, paper and cardboard material, or a combination thereof.
- said substrate comprises a plurality of channels and/or cells suitable for the passage of a fluid, said channels and/or cells having a cross section preferably selected from among circular, hexagonal, square, triangular, rectangular and a combination thereof, and identifying a path for the fluid having a variable geometry; said substrate preferably having a structure selected from among: a stratified structure, an interwoven structure, a fabric weave structure and a honeycomb structure, preferably characterised by a CPSI (cells per square inch) value of from 40 to 120, and a combination thereof.
- CPSI cells per square inch
- the present invention relates to the use of nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight, a substrate nanofunctionalised with said nanoparticles, a device comprising at least one substrate nanofunctionalised with said nanoparticles and at least one light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm, for killing a pathogenic agent, said pathogenic agent preferably being selected from viruses and/or bacteria and/or fungi as described in the present patent application.
- the present invention also relates to a method for killing said pathogenic agent, comprising the steps of:
- Figures 1A and 1 B show SEM images, in two different magnifications, of a detail of the surface of the nanofunctionalised substrate, i.e. the substrate coated by T1O2-N nanoparticles obtained as described in Example 2.
- nitrogen-doped T1O2 (T1O2- N) nanoparticles” or “nitrogen-doped titanium dioxide (T1O2-N) nanoparticles” refer to (photocatalytic) nanoparticles doped exclusively with nitrogen. Such expressions therefore exclude so-called “co-doping”, that is, the simultaneous presence of two or more doping elements/agents, such as, for example in the case of nitrogen-rare earth doping or the like.
- nanoparticle suspension for the purposes of the present invention, are considered synonymous and refer to a mixture in which finely divided solid nanoparticles are dispersed in a solvent, for example water and/or alcohol, so that they are not sedimentable or, after a possible sedimentation, are easily re-dispersible.
- a solvent for example water and/or alcohol
- nanoparticle coating for the purposes of the present invention, means a coating comprising nanoparticles or consisting of nanoparticles.
- polymeric material or “plastic material” means, for the purposes of the present invention, a wide range of synthetic or semi-synthetic, high-molecular weight polymeric organic compounds, which are malleable and can thus be modelled into solid objects.
- Said polymeric organic compounds can be pure (co)polymers or comprise other substances aimed at improving the properties and reducing the costs thereof, such as, for example organic and/or inorganic additives.
- (co)polymer is used to indicate both polymers, also called homopolymers, i.e. macromolecules whose polymeric chain contains repetitive units obtained from the union of monomers of only one type, and copolymers, i.e. macromolecules whose polymeric chain contains repetitive units obtained from the union of monomers of two or more different types.
- transparent refers to the physical property of transparency, i.e. the property which allows light to pass through a material.
- a material is defined “transparent” if it transmits light and enables a clear observation of an object through it.
- translucid refers to the physical property of translucency, which allows light to pass through a material in a diffused manner.
- a material is defined as “translucid” if it transmits light by diffusing it but is not transparent, i.e. if said material does not enable a clear observation of an object observed through it.
- opaque refers to the physical property of opacity, which does not allow light to pass through a material.
- a material is defined as “opaque” if it does not transmit light, i.e. if it is impenetrable to light and thus totally prevents the observation of an object through it.
- substrate nanofunctionalised with nitrogen-doped T1O2 nanoparticles and synonyms mean a substrate that comprises said nanoparticles.
- Said nanoparticles can be present within the material/materials that forms/form the substrate or can form/be present within a nanoparticle coating that covers (totally or partly) at least one surface of the substrate, be it an inner and/or outer surface.
- inner and/or outer surface of the substrate means, for the purposes of the present invention, any surface of the substrate, whether it is visible from the outside (outer surface) or, in the case of a more complex geometry and/or shape of the substrate comprising, for example, cavities, channels and/or interstices, not visible from the outside (inner surface).
- a substrate produced with the shape and geometry of a hollow sphere will have an outer surface visible to the observer and an inner surface facing towards the hollow internal space and thus not directly visible to the observer.
- the term “substrate” is to be understood as a synonym of “support”.
- the expressions containing the term “substrate” described in the present patent application i.e. “nanofunctionalised substrate” etc.
- the expressions containing the term “substrate” described in the present patent application are to be understood as containing the term “support” (i.e. “nanofunctionalised support”, etc.).
- macroroughness means the property possessed by a surface of a body consisting of geometric micro imperfections, intrinsic or resulting from machining; such imperfections, measured by means of a roughness tester or by observation with an electron microscope, generally appear in the form of depressions and/or scratches, of variable shape, depth and direction and having a size in the order of micrometres or millimetres.
- nanoroughness means the property, measured by means of an electron microscope, tied to the presence of nanoparticles within a material and/or as a coating on the surface thereof, and which renders the surface thereof “rough” on a nanometric scale, i.e. a surface that exhibits imperfections in the form of protuberances, mountains and valleys having a size in the in the order of nanometres.
- UV light means ultraviolet radiation, i.e. the range of electromagnetic radiation with a wavelength immediately below that of light visible to the human eye and immediately above that of X-rays, i.e. with a wavelength comprised between about 10 and about 380 nm.
- visible light means visible radiation, i.e. the range of electromagnetic radiation with a wavelength immediately above that of ultraviolet radiation and immediately below that of infrared radiation, i.e. with wavelength comprised between about 380 and about 720 nm.
- sun means solar radiation, i.e. the radiant energy emitted in interplanetary space by the sun, which comprises electromagnetic radiation at various wavelengths.
- about 50% of solar radiation is emitted in the infrared region (NIR, near the visible region and comprised between about 750 nm and about 1500 nm), about 5% in the ultraviolet region and the rest in the visible region.
- NIR infrared region
- fluid refers to a material (i.e. a substance or a mixture of several substances) which deforms unlimitedly (flows) if subjected to a shear strain, irrespective of the entity of the latter.
- the term “fluid” is therefore used to indicate the state of matter that comprises liquids, aeriform substances (gases), plasma and plastic solids.
- T1O2 nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight for killing a virus and/or for killing fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or for killing bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micrococcaceae, Mycobacteriaceae, Spirochaetaceae, Leptospiraceae, and a combination thereof.
- T1O2-N nitrogen-doped
- the present invention relates to a use of nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight for killing a pathogenic agent, said pathogenic agent preferably being selected from among said virus and/or said fungi and/or said bacteria, as described in the present patent application.
- said T1O2-N nanoparticles activatable by UV light and/or visible light and/or sunlight are in the form of a powder, preferably calcined powder.
- the expressions “nanoparticles in the form of a (calcined) powder” or “(calcined) nanoparticle powder” are to be understood as synonyms.
- said T1O2-N nanoparticles activatable by UV light and/or visible light and/or sunlight are in the form of a suspension in a solvent, preferably selected in the group consisting of: an organic solvent, water or a mixture thereof.
- a solvent preferably selected in the group consisting of: an organic solvent, water or a mixture thereof.
- said organic solvent is selected in the group consisting of: ethyl alcohol, acetone, glycol, preferably selected in the group consisting of: diethylene glycol (DEG), polyethylene glycol (PEG), monopropylene glycol (MPG), monoethylene glycol (MEG), and a combination thereof; or a mixture thereof.
- said organic solvent comprises a mixture of ethyl alcohol and at least one glycol, or a mixture of acetone and at least one glycol; said at least one glycol, preferably being selected in the group consisting of: diethylene glycol (DEG), polyethylene glycol (PEG), monopropylene glycol (MPG), monoethylene glycol (MEG), and a combination thereof.
- said solvent comprises a mixture of said organic solvent and water, preferably a mixture of at least one glycol and water; said at least one glycol, preferably being selected in the group consisting of: diethylene glycol (DEG), polyethylene glycol (PEG), monopropylene glycol (MPG), monoethylene glycol (MEG), and a combination thereof.
- said PO2-N nanoparticles are present in said suspension in an amount comprised between 0.1 and 20% by weight, preferably between 1 and 10% by weight relative to the total weight of the suspension.
- said suspension of PO2-N nanoparticles activatable by UV light and/or visible light and/or sunlight has a density comprised between 0.6 and 1 g/cm 3 , more preferably between 0.7 and 0.9 g/cm 3 and, preferably, a viscosity comprised between 0.8 and 1.3 mPa*s, more preferably between 0.9 and 1.1 mPa*s, measured at 25 °C.
- said suspension of PO2-N nanoparticles activatable by UV light and/or visible light and/or sunlight has a density comprised between 0.6 and 1.1 g/cm 3 , more preferably between 0.7 and 0.9 g/cm 3 and, preferably, a viscosity comprised between 30 and 80 mPa*s, more preferably between 35 and 75 mPa*s, measured at 25 °C.
- said T1O2-N nanoparticles activatable by UV light and/or visible light and/or sunlight are comprised within a colour coating or a paint.
- said T1O2-N nanoparticles have a size between 30 and 150 nm, more preferably between 35 and 100 nm, even more preferably between 48 and 150 nm, even more preferably between 48 and 100 nm, even more preferably between 30 and 50 nm, even more preferably between 30 and 80 nm, even more preferably between 48 and 90 nm, measured as a Z-average with the DLS technique (Dynamic Light Scattering, Malvern Instruments).
- DLS technique Dynamic Light Scattering, Malvern Instruments
- the range of 30-150 nm means that the nanoparticles have a Z-average equal to a whole or decimal number comprised between 30 and 150 nm, with a polydispersity index less of than 0.3, preferably comprised between 0.21 and 0.29, more preferably comprised between 0.216 and 0.286.
- Such polydispersity values indicate an excellent uniformity in the size of the nanoparticles. Therefore, if for example the Z- average value of the nanoparticles is equal to 49.9 with a polydispersity index of 0.221, this means that the nanoparticles are evenly distributed from a dimensional viewpoint and that almost all of them have an average diameter of about 49.9 nm.
- the amount of doping nitrogen present in said T1O2-N nanoparticles is comprised between 1 and 5% by weight, preferably between 1.5 and 3% by weight relative to the total weight of the nanoparticles.
- said T1O2-N nanoparticles activatable by UV light and/or visible light and/or sunlight have a considerable photocatalytic activity, in particular a considerable activity of oxidative photocatalysis, since, under irradiation (with UV light and/or visible light and/or sunlight), said nanoparticles become a powerful oxidant and show to be surprisingly and particularly effective in killing a virus and/or fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or bacteria, said bacteria being selected in the group consisting of: Streptoco
- said T1O2-N nanoparticles have, as determined by X-ray diffraction analysis, at least a brookite crystalline phase in an amount of 10 to 99% by weight relative to the weight of the nanoparticles.
- said T1O2-N nanoparticles further have a rutile crystalline phase.
- said T1O2-N nanoparticles that have at least a brookite crystalline phase and a rutile crystalline phase also further have an anatase crystalline phase.
- said T1O2-N nanoparticles have a brookite crystalline phase in an amount of 90 to 99% by weight relative to the weight of the nanoparticles, the remaining amount to 100% being a rutile and/or anatase crystalline phase.
- said T1O2- N nanoparticles have at least two crystalline phases of T1O2: a brookite crystalline phase in an amount of 10 to 99% by weight relative to the weight of the nanoparticles and a rutile crystalline phase (and/or an anatase crystalline phase) in an amount of 25 to 90% by weight relative to the weight of the nanoparticles.
- said amount of the brookite crystalline phase from “10 to 99% by weight” means that said brookite crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes as described above.
- said amount of the rutile and/or anatase crystalline phase from “25 to 90% by weight” means that said rutile and/or anatase crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes, as described above.
- said T1O2-N nanoparticles have at least two crystalline phases ofPO2: a brookite crystalline phase in an amount of 10 to 75% by weight relative to the weight of the nanoparticles and a rutile crystalline phase (and/or an anatase crystalline phase) in an amount of 25 to 90% by weight relative to the weight of the nanoparticles.
- said amount of the brookite crystalline phase from “10 to 75% by weight” means that said brookite crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes, such as, for example, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%,
- said amount of the rutile and/or anatase crystalline phase from “25 to 90% by weight” means that said rutile and/or anatase crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes, as described above.
- said PO2-N nanoparticles have a rutile crystalline phase (and/or an anatase crystalline phase) and a brookite crystalline phase, each preferably present in an amount equal to about 50% by weight relative to the weight of the nanoparticles.
- said PO2-N nanoparticles have three crystalline phases of PO2: a brookite crystalline phase in an amount of 20 to 75%, an anatase crystalline phase in an amount of 35 to 80% and a rutile crystalline phase in an amount of 35 to 40% by weight relative to the weight of the nanoparticles.
- said amount of the brookite crystalline phase from “20 to 75% by weight” means that said brookite crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes, such as, for example, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%,
- said amount of the anatase crystalline phase from “35 to 80% by weight” means that said anatase crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes, such as, for example, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%,
- said amount of the rutile crystalline phase from “35 to 40% by weight” means that said rutile crystalline phase can be present in an amount equal to any value comprised between the two aforesaid extremes, such as, for example, 35%, 36%, 37%, 38%, 39%, 40%.
- the present invention relates to the use - for killing a virus and/or for killing fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or for killing bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micrococcaceae, Mycobacteriaceae, Spirochaetaceae, Leptospiraceae, and a combination thereof - of nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and
- the better activity of the brookite phase compared to the other two crystalline phases of PO2 can be linked to the fact that, since the photocatalytic activity depends on the number of PO2 molecules per cell units, and the brookite phase has a greater cell volume, it has a larger amount of surface oxygen available for photocatalysis and therefore for killing said virus and/or said fungi and/or said bacteria.
- the present invention relates to a use of nitrogen-doped PO2 (PO2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight for killing a virus and/or for killing fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or for killing bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micrococcaceae, Mycobacteriaceae, Spirochaetaceae, Leptospiraceae, and a combination thereof, said nanoparticles being
- a silver nitrate or sulphate, or silver nanoparticles a silver nitrate or sulphate, or silver nanoparticles
- manganese oxide (IV) MnC>2
- zinc oxide ZnO
- a source of copper in the form of a copper salt, e.g. a copper nitrate or sulphate, or copper nanoparticles
- said PO2-N nanoparticles are as previously described.
- said PO2-N nanoparticles are in combination with said at least one further virucidal and/or bactericidal and/or fungicidal agent in the form of a mixture (suspension) in a solvent, preferably in an organic solvent, for example ethyl alcohol, acetone or glycol, preferably selected in the group consisting of: diethylene glycol (DEG), polyethylene glycol (PEG), monopropylene glycol (MPG), monoethylene glycol (MEG), and a combination thereof, or mixtures thereof, or in water, or in a mixture of water and an organic solvent, or in the form of a powder mixture.
- a solvent preferably in an organic solvent, for example ethyl alcohol, acetone or glycol, preferably selected in the group consisting of: diethylene glycol (DEG), polyethylene glycol (PEG), monopropylene glycol (MPG), monoethylene glycol (MEG), and a combination thereof, or mixtures thereof, or in water, or in a mixture of
- said organic solvent comprises a mixture of ethyl alcohol and at least one glycol, or a mixture of acetone and at least one glycol.
- said solvent comprises a mixture of said organic solvent and water, preferably a mixture of water and at least one glycol.
- said at least one glycol is selected in the group consisting of: diethylene glycol (DEG), polyethylene glycol (PEG), monopropylene glycol (MPG), monoethylene glycol (MEG), and a combination thereof.
- the amount of silver and/or Mn02 and/or ZnO and/or Cu present in the suspension or final powder mixture (in combination with said PO2-N nanoparticles) is preferably greater than 20 ppm.
- said nitrogen-doped PO2 ( PO2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight as previously described are obtained/obtainable in the form of a calcined powder by means of the process described in WO2019/211787 of the same Applicant, entirely incorporated herein by reference, which comprises the steps of: a) preparing a suspension of PO2 nanoparticles in water; b) adding a nitrogen doping agent to the suspension and mixing until homogeneous; c) drying the suspension to which the nitrogen doping agent was added until obtaining a powder with a moisture residue comprised between 0 and 15% by weight; d) subjecting the dried powder to calcination at a temperature comprised between 400 and 600 °C, thereby obtaining nitrogen-doped PO2 (PO2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight in the form of a calcined powder.
- Said nitrogen-doped PO2 (PO2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight are preferably obtained/obtainable in the form of a suspension, if, in addition to steps a)-d) described above, the process comprises the further steps of: e) subjecting the calcined powder obtained in step d) to grinding in a solvent, thereby obtaining a suspension of PO2-N nanoparticles activatable by UV light and/or visible light and/or sunlight in a solvent; f) diluting the suspension of step e) with further solvent.
- the suspension of T1O2 nanoparticles in water of step a) is a stable suspension prepared according to the process described in W0200788151 of the same Applicant, entirely incorporated herein by reference.
- the suspension of PO2 nanoparticles in water of step a) is a suspension ofPO2 nanoparticles having a size comprised between 30 and 50 nm, measured with methods known in the art, such as FEG-SEM (scanning electron microscopy), TEM (transmission electron microscopy) and DLS (Dynamic Light Scattering).
- the polydispersity index of the nanoparticles is less than 0.3, preferably comprised between 0.21 and 0.29, more preferably between 0.216 and 0.286.
- the concentration of T1O2 nanoparticles suspended in water is comprised between 1 and 10% by weight, preferably between 2 and 8% by weight relative to the weight of the suspension.
- the suspension of nanoparticles is stable for very long periods without manifesting phenomena of coagulation or conglomeration. Therefore, said suspension can be prepared with the process of W0200788151 and then stored, also for a long time, before being used in step (a).
- the process for obtaining the suspension of T1O2 nanoparticles in water, preferably in anatase crystalline form comprises a first step in which a titanium alkoxide in water is subjected to acid hydrolysis at a temperature comprised between 15 and 95 °C and for a time comprised between 12 hours and 72 hours, in the presence of a non-ionic surfactant, preferably Triton X-100.
- the titanium alkoxide is selected from among titanium methoxide, titanium ethoxide, titanium normal- propoxide, titanium isopropoxide, titanium normal-butoxide and titanium isobutoxide.
- the preferred alkoxide is titanium propoxide.
- the mineral acid used for the acid hydrolysis of the titanium alkoxide is selected from among: hydrochloric acid, nitric acid, sulphuric acid, perchloric acid, hydrobromic acid and hydrogen iodide.
- a nitrogen doping agent selected from an inorganic ammonium salt and an organic nitrogen compound is added to the suspension of T1O2 nanoparticles in water, preferably in anatase crystalline form.
- the nitrogen doping agent is preferably selected from ammonium citrate and triethanolamine.
- Ammonium citrate has provided better results in terms of process and ease of drying of the suspension than triethanolamine and is thus the preferred nitrogen doping agent.
- the nitrogen doping agent is added to the aqueous suspension of T1O2 nanoparticles in an amount preferably comprised between 2 and 6% by weight, preferably between 3 and 5% by weight.
- the addition of the nitrogen doping agent to the aqueous suspension of T1O2 nanoparticles takes place under stirring and the formation of a white gel is observed.
- the suspension is then kept under stirring for a time preferably comprised between 4 and 24 hours, that is, until a homogeneous white suspension is obtained.
- the suspension obtained preferably comprises from 4 to 8% by weight of T1O2 and from 6 to 30% by weight of nitrogen relative to the weight of TiC>2.
- the suspension preferably comprises from 5 to 7% by weight of T1O2 and from 8 to 25% by weight of nitrogen relative to the weight of TiC>2.
- the suspension obtained preferably comprises T1O2 nanoparticles having a size comprised between 48 and 150 nm, measured as the Z-average with DLS (Dynamic light scattering, Malvern Instruments).
- the range of 48-150 nm means that the nanoparticles have a Z-average equal to a whole or decimal number comprised between 48 and 150 nm, with a polydispersity index of less than 0.3, preferably comprised between 0.21 and 0.29, more preferably between 0.216 and 0.286.
- Such polydispersity values indicate an excellent uniformity in the size of the nanoparticles of the suspension. Therefore, if for example the Z-average of the nanoparticles is equal to 49.9 with a polydispersity index of 0.221 , this means that the suspension comprises very uniform nanoparticles, almost all of which have an average diameter of about 49.9 nm.
- the suspension of T1O2 nanoparticles also comprising the nitrogen doping agent thus obtained is subjected to drying in step c) by means of the spray-drying technique, or electric or gas ovens, or by heating with microwaves.
- the latter treatment is to be preferred, since the process shows to be more efficient and faster compared to the use of the conventional spray-drying technique; furthermore, the treatment with microwaves makes it possible to obtain a powder with a lesser degree of aggregation/agglomeration, which makes the subsequent optional grinding step (step e)) more efficient.
- the drying temperature is preferably comprised between 100 and 150 Q C, preferably between 110 and 140 Q C. Drying can last from 10 to 24 hours, preferably from 15 to 20 hours.
- the particle size of the powder is preferably less than 20 pm, more preferably less than 15 pm, calculated with laser diffraction using a Sympatec HELOS (Model H0969).
- 99% of the powder particles have a size of less than 15 pm and 90% of the powder particles have a size of less than 11 pm. More preferably, 50% of the powder particles have a size of less than 5.5 pm and 10% of the powder particles have a size of less than 2 pm.
- the calcination of step d) preferably takes place at a temperature comprised between 450 and 500 °C.
- heating is carried out by treating the dried powder in a muffle furnace or by means of microwaves.
- the latter treatment is to be preferred, since the process shows to be more efficient and faster compared to conventional heating in a muffle furnace; furthermore, the treatment with microwaves makes it possible to obtain a powder with a lesser degree of aggregation/agglomeration, which makes the subsequent optional grinding step (step e)) more efficient.
- the calcination is preferably carried out for a time comprised between 1 and 2 hours, more preferably with a ramp of 1 or 2 hours to arrive at the calcination temperature.
- the heating gradient can be comprised between 7 and 14 Q C per minute.
- the nitrogen doping of T1O2 takes place; the nitrogen penetrates into the T1O2 nanoparticles, positioning itself in a substitution position within the crystal lattice of the T1O2 and/or in an interstitial position, that is, within the crystal planes of the TiC>2.
- the calcined powder is obtained as a powder of nitrogen-doped T1O2 (T1O2-N) nanoparticles and, for the purposes of the present invention, it is also called “nanoparticle powder”.
- the calcined powder is obtained as an aggregate powder of nitrogen-doped T1O2 (T1O2-N) which, according to X-ray diffraction analysis, has at least a brookite crystalline phase in an amount of 10 to 99% by weight relative to the weight of the calcined powder.
- said calcined powder further comprises a rutile crystalline phase.
- the calcined powder comprising at least a brookite crystalline phase and a rutile crystalline phase further comprises an anatase crystalline phase as well.
- the calcined powder comprises from 90 to 99% by weight, relative to the weight of the calcined powder, of a brookite crystalline phase of T1O2, the remaining amount to 100% being a rutile and/or anatase crystalline phase.
- the calcined T1O2-N powder comprises at least two crystalline phases of T1O2: a brookite crystalline phase in an amount of 10 to 99% by weight relative to the weight of the calcined powder and a rutile crystalline phase (and/or an anatase crystalline phase) in an amount of 25 to 90% by weight relative to the weight of the calcined powder.
- the calcined T1O2-N powder comprises at least two crystalline phases of T1O2: a brookite crystalline phase in an amount of 10 to 75% by weight relative to the weight of the calcined powder and a rutile crystalline phase (and/or an anatase crystalline phase) in an amount of 25 to 90% by weight relative to the weight of the calcined powder.
- the calcined powder comprises a rutile crystalline phase (and/or an anatase crystalline phase) and a brookite crystalline phase, each preferably present in an amount equal to about 50% by weight relative to the weight of the calcined powder.
- the calcined powder comprises three crystalline phases of the T1O2: a brookite crystalline phase in an amount of 20 to 75%, an anatase crystalline phase in an amount of 35 to 80% by weight relative to the weight of the calcined powder and a rutile crystalline phase in an amount of 35 to 40% by weight relative to the weight of the calcined powder.
- the calcined powder has a degree of purity greater than 95% by weight, preferably equal to or greater than 99% by weight, since the diffraction analysis did not reveal the presence of phases other than the crystalline phases of T1O2 described above.
- the aforesaid ranges of the amount of brookite, rutile and anatase crystalline phases mean that said crystalline phases can be present in an amount equal to any value comprised between the two aforesaid extremes of the aforesaid ranges, as described above.
- said calcined powder obtained in step d) has an amount of doping nitrogen present in the TiC>2 comprised between 1 and 5% by weight, preferably between 1.5 and 3% by weight, relative to the total weight of the calcined powder.
- the Applicant deems that the formation of a calcined powder of nitrogen doped TiC>2 comprising at least one brookite crystalline phase is ascribable mainly to the use of the TiC>2 suspension obtained with the process of W0200788151 , but probably also to a combination between the use of this starting product, and the drying and calcination steps as just described.
- the presence of the brookite phase is a surprising and unexpected result, considering that the starting product consists essentially of T1O2 in the anatase phase.
- the brookite phase brings some considerable advantages as regards the photocatalytic properties of the T1O2-N nanoparticles, in particular proving to be particularly efficient in the use for killing a virus and/or for killing fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or for killing bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae,
- said calcined powder can be subjected to wet grinding and then re-dispersed in a solvent, according to steps e) and f) described below.
- the calcined powder can be finely dispersed with or without a grinding and dilution pre treatment according to steps e) and f), within colour coatings and paints used to coat floors, walls or exterior and/or interior surfaces, for example of buildings, in order to render them antiviral and/or antibacterial and/or antifungal, and thus capable of killing viruses and/or fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae,
- Staphylococcaceae Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micrococcaceae, Mycobacteriaceae, Spirochaetaceae, Leptospiraceae, and a combination thereof.
- said nitrogen-doped PO2 (PO2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight are obtained/obtainable in the form of a suspension, if, in addition to steps a)-d) described above, the process comprises the further steps of: e) subjecting the calcined powder obtained in step d) to grinding in a solvent, thereby obtaining a suspension of PO2-N nanoparticles activatable by UV light and/or visible light and/or sunlight in a solvent; f) diluting the suspension of step e) with further solvent.
- the calcined powder is preferably subjected to grinding in a high-energy ball mill with the aid of a solvent, for example water, acetone, ethyl alcohol or mixtures thereof.
- a solvent for example water, acetone, ethyl alcohol or mixtures thereof.
- the grinding takes place at a speed preferably comprised between 1000 and 2000 rpm for a time comprised between 30 and 120 minutes, more preferably between 80 and 100 minutes.
- concentration values of the T1O2-N nanoparticles comprised, for example, between 15 and 30% by weight.
- the suspension obtained after grinding is a suspension of T1O2-N nanoparticles in an organic solvent, for example ethyl alcohol or acetone or mixtures thereof, or in water, or in mixtures of water and an organic solvent.
- the size of the nanoparticles is preferably comprised between 48 and 150 nm, measured as a Z-average with DLS (Dynamic light scattering, Malvern Instruments).
- the range of 48-150 nm means that the nanoparticles have a Z-average equal to a whole or decimal number comprised between 48 and 150 nm, with a polydispersity index of less than 0.3, preferably comprised between 0.21 and 0.29, more preferably between 0.216 and 0.286.
- Such polydispersity values indicate an excellent uniformity in the size of the nanoparticles of the suspension. Therefore, if for example the Z-average value of the nanoparticles is equal to 49.9 with a polydispersity index of 0.221 , this means that the suspension comprises very uniform nanoparticles, almost all of which have an average diameter of about 49.9 nm.
- the suspension obtained at the end of step e) can be too concentrated and have a rheology that is not suitable for some industrial applications, above all for applications on substrates.
- the process as described above preferably also comprises a subsequent step f), wherein the suspension is further diluted in the same solvent, preferably in an organic solvent or water or mixtures thereof, such as, for example ethyl alcohol, acetone, water or mixtures thereof.
- the final concentration of the T1O2-N powder in the solvent is thus preferably brought to values comprised between 0.1 and 20% by weight, preferably between 1 and 10% by weight.
- the rheology of the suspension is preferably characterised by a density comprised between 0.6 and 1 g/cm 3 , more preferably between 0.7 and 0.9 g/cm 3 and, preferably, by a viscosity comprised between 0.8 and 1.3 mPa*s, more preferably between 0.9 and 1.1 mPa*s, measured at 25 °C.
- a density comprised between 0.6 and 1 g/cm 3 , more preferably between 0.7 and 0.9 g/cm 3 and, preferably, by a viscosity comprised between 0.8 and 1.3 mPa*s, more preferably between 0.9 and 1.1 mPa*s, measured at 25 °C.
- suitable additives known in the art for this type of function, for example carboxymethylcellulose and glycols.
- the rheology of the suspension is important in order to be able to use the suspension, preferably on an industrial scale, in particular in order to be able to apply the suspension to substrates of varying nature by means of the “spray coating”, “flow coating”, “dip coating”, “spin coating”, “Meyer bar coating”, “gravure coating”, “knife coating”, “kiss coating”, “die coating” or “film transfer” techniques.
- step f) of diluting the suspension it is possible to add to the suspension of T1O2-N nanoparticles at least one further virucidal and/or bactericidal and/or fungicidal agent such as, for example a source of silver (in the form of a silver salt, e.g. a silver nitrate or sulphate, or silver nanoparticles), manganese oxide (IV) (MnC>2) nanoparticles, zinc oxide (ZnO) nanoparticles, a source of copper (in the form of a copper salt, such as, for example a copper nitrate or sulphate, or copper nanoparticles), or a mixture thereof.
- a source of silver in the form of a silver salt, e.g. a silver nitrate or sulphate, or silver nanoparticles
- manganese oxide (IV) (MnC>2) nanoparticles manganese oxide (IV) (MnC>2) nanoparticles, zinc oxide
- the amount of silver and/or MnC and/or ZnO and/or Cu present in the final suspension is preferably greater than 20 ppm.
- the suspension of T1O2-N nanoparticles obtained at the end of the process as described above comprises nanoparticles with the same crystalline phases as shown in the calcined powder. The percentages by weight indicated are to be understood as percentages by weight of the crystalline phase relative to the weight of the nanoparticles.
- the T1O2-N nanoparticles in suspension have a nitrogen doping content preferably comprised between 1 and 5% by weight, preferably between 1.5 and 3% by weight relative to the weight of the nanoparticles.
- the suspension of T1O2-N nanoparticles is a suspension in a solvent, preferably ethyl alcohol, acetone, water or mixtures thereof.
- the T1O2-N nanoparticles are present in the suspension in an amount comprised between 0.1 and 20% by weight, preferably between 1 and 10% by weight, preferably in an alcoholic organic solvent, water or mixtures thereof, such as, for example ethyl alcohol or mixtures thereof with water.
- the solvent is thus present in an amount comprised between 80 and 99.9% by weight.
- the suspension of T1O2-N nanoparticles can be defined as a ready-to-use suspension, as it has chemical and physical characteristics, e.g. rheology, such as to enable it to be used without further treatments to coat substrates by means of the coating techniques listed above. Furthermore, the suspension thus obtained is stable for over 6 months without the formation of precipitates or phase separations.
- the subject matter of the present invention also relates to a use of a substrate nanofunctionalised with nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight for killing a virus and/or for killing fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or for killing bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micrococcaceae, Mycobacteriaceae, Spirochaetaceae, Leptospiraceae,
- the present invention also relates to a use of a substrate nanofunctionalised with nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight for killing a pathogenic agent, said pathogenic agent preferably being selected from among said virus and/or said fungi and/or said bacteria, as described in the present patent application.
- said nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight are as previously described.
- said nanofunctionalised substrate is entirely or partly coated with said nitrogen-doped PO2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight, and/or comprises said nanoparticles within it.
- the expression “entirely or partly coated with nitrogen-doped PO2 nanoparticles”, means that said nanoparticles form/are present within a nanoparticle coating that entirely or partly coats at least one surface of the substrate, be it an inner and/or outer surface.
- “Entirely coated” means that the substrate has all inner and/or outer surfaces coated with the nitrogen-doped PO2 nanoparticles.
- the inner and/or outer surfaces of the substrate have, overall, a percentage of coverage greater than 95%, preferably greater than 98%.
- “Partly coated” means that the inner and/or outer surfaces of the substrate have, overall, a percentage of coverage less than 95%, preferably less than 98%. In this case, for example, only some of the surfaces of the substrate may be coated with the nitrogen-doped PO2 nanoparticles.
- the nanoparticle coating preferably has a thickness, measured by means of an electron microscope, comprised between 1 and 5 pm, preferably between 1.5 and 3 pm, more preferably between 1.8 and 2.6 pm.
- nanofunctionalised substrate comprises an amount of T1O2-N nanoparticles comprised between 1 and 10 g/m 2 , preferably between 2 and 8 g/m 2 , even more preferably between 4 and 7 g/m 2 .
- said substrate nanofunctionalised with nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight further comprises at least one virucidal and/or bactericidal and/or fungicidal agent preferably selected from among: a source of silver (in the form of a silver salt, e.g. a silver nitrate or sulphate, or silver nanoparticles), manganese oxide (IV) (MnC>2) nanoparticles, zinc oxide (ZnO) nanoparticles, a source of copper (in the form of a copper salt, e.g.
- said at least one further virucidal and/or bactericidal and/or fungicidal agent is comprised, together with the nitrogen-doped T1O2 nanoparticles, within a nanoparticle coating that entirely or partly coats at least one surface of the substrate, be it an inner and/or outer surface.
- said at least one further virucidal and/or bactericidal and/or fungicidal agent in turn forms a complete or partial coating on said PO2-N nanoparticle coating.
- said at least one further virucidal and/or bactericidal and/or fungicidal agent is comprised, together with the nitrogen-doped PO2 nanoparticles, within the material/materials forming the substrate.
- said at least one further virucidal and/or bactericidal and/or fungicidal agent is comprised, together with the nitrogen-doped PO2 nanoparticles, within the material/materials forming the substrate.
- the amount of silver and/or MnCte and/or ZnO and/or Cu present as a coating of the and/or comprised within the substrate is preferably greater than 20 ppm.
- said substrate is selected in the group consisting of: a substrate of ceramic material, preferably said ceramic material being selected from among cordierite, mullite, alumina and a combination thereof; a substrate of polymeric material, said polymeric material preferably comprising at least one (co)polymer selected from among: PMMA (polymethylmethacrylate), PA (polyamide), PC (polycarbonate), PLA (polylactic acid), PET (polyethylene terephthalate), PE (polyethylene), PVC (polyvinyl chloride), PS (polystyrene), acrylonitrile styrene acrylate (ASA), acrylonitrile butadiene styrene (ABS), polyethylene terephthalate glycol (PET-g), polyurethane (PU), polypropylene (PP), copolyester, and a combination thereof; a substrate of textile material, nonwoven fabric, metal, glass, paper and cardboard material, or a combination thereof.
- a substrate of textile material non
- said substrate is a substrate selected from among: cordierite, mullite, alumina, acrylonitrile butadiene styrene (ABS) and polyethylene terephthalate glycol (PET-g), preferably acrylonitrile butadiene styrene (ABS).
- ABS acrylonitrile butadiene styrene
- PET-g polyethylene terephthalate glycol
- Said nanofunctionalised substrate can preferably be obtained/obtainable by means of any process known in the art which enables a complete or partial coating with the nitrogen-doped T1O2 nanoparticles (as previously described, optionally in combination with at least one further virucidal and/or bactericidal and/or fungicidal agent), or which enables the inclusion of said nanoparticles within the material/materials forming the substrate itself, said process preferably being selected from among the techniques of: “spray coating”, “flow coating”, “dip coating”, “spin coating”, “Meyer bar coating”, “gravure coating”, “knife coating”, “kiss coating”, “die coating” or “film transfer”, optionally followed by a calcination step; 3D printing, injection moulding, extrusion, or a combination thereof.
- said nanofunctionalised substrate is opaque, translucid or transparent.
- said nanofunctionalised substrate is translucid or transparent so as to be able to advantageously exploit up to 100% of the luminous radiation (i.e. UV light and/or visible light and/or sunlight) when it is incident on the substrate and can thus be respectively diffused by or passes through the substrate, thereby obtaining superior photocatalytic performances (in terms of killing said virus and/or said fungi and/or said bacteria) of the T1O2-N nanoparticles activatable by UV light and/or visible light and/or sunlight as previously described.
- the nanofunctionalised substrate is transparent.
- said nanofunctionalised substrate comprises a plurality of channels and/or cells suitable for the passage of a fluid.
- said channels and/or cells have a cross section with variable geometry, preferably selected from among circular, hexagonal, square, triangular, rectangular and a combination thereof. More preferably, said channels and/or cells identify a path for a fluid, said path having a variable geometry. Said path is preferably selected from among linear, tortuous, spiral or a combination thereof.
- said nanofunctionalised substrate has a structure selected in the group consisting of: a stratified structure, an interwoven structure, a fabric weave structure and a honeycomb structure, preferably with a variable cell number and/or shape, said shape being for example selected from among circular, hexagonal, square, triangular, rectangular and a combination thereof.
- the nanofunctionalised substrate can comprise several layers in variable numbers and sizes, each layer preferably having a structure as previously described.
- the nanofunctionalised substrate according to this embodiment preferably comprises at least two layers joined to each other by means of an interlock mechanism or with a plug system. The selection of the number of layers and the assembly thereof and of their structure will vary according to the fluid-dynamic characteristics it is desired to obtain.
- the nanofunctionalised substrate has a honeycomb structure.
- said substrate with a honeycomb structure comprises a matrix of walls, preferably thin walls, which define a plurality of parallel conduits that are open at both ends so as to allow the passage of a fluid, preferably air and/or water.
- said plurality of conduits defines a plurality of oxidation sites in which, through the activation of the photocatalytic properties of the T1O2-N nanoparticles activatable by UV light and/or visible light and/or sunlight comprised within the material(s) forming the substrate itself and/or in the form of a coating of said walls, there occurs an effective killing, by an incident photon, of a virus and/or of fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or of bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae,
- Said honeycomb structure is preferably characterised by a CPSI (cells per square inch) value comprised between 40 and 120, preferably between 50 and 100, more preferably between 50 and 70, even more preferably between 55 and 65.
- CPSI cells per square inch
- said nanofunctionalised substrate is a substrate made of polymeric material characterised by a nanoroughness, measured by means of an electron microscope, comprised between 10 and 50 nm and a macroroughness, measured by means of an electron microscope, comprised between 100 and 600 pm, wherein said nano- and macroroughness is diffused internally and/or superficially.
- said nanoroughness is comprised between 20 and 40 nm and said macroroughness is comprised between 200 and 300 pm.
- nano-/macroroughness diffused internally and/or superficially means that said substrate can exhibit said nanoroughness and macroroughness in every part thereof, i.e.
- said macroroughness is connected to the polymeric material and/or the processing thereof to obtain the substrate itself.
- said processing is selected in the group consisting of: the 3D printing, injection moulding and extrusion techniques, optionally followed by further operations suitable for creating macroroughness.
- said nanoroughness derives from the functionalisation of the substrate with the T1O2-N nanoparticles as described above (optionally in combination with at least one further virucidal and/or bactericidal and/or fungicidal agent as previously described) which, once in contact with the polymeric material characterised by said macroroughness, become organised so as to create a characteristic nanoroughness.
- said T1O2-N nanoparticles are present (i.e. comprised) within said polymeric material or that they are present both therewithin and in the form of a nanoparticle coating, in this case one can speak of nanoroughness that is both internally and superficially diffused.
- said PO2-N nanoparticles are present solely in the form of a nanoparticle coating on at least one inner and/or outer surface of said substrate, in this case one can speak only of superficially diffused nanoroughness.
- the Applicant has surprisingly found that, thanks to the combination of said nanoroughness comprised between 10 and 50 nm and of said macroroughness, measured by means of an electron microscope, comprised between 100 and 600 pm, it is possible to obtain a nanofunctionalised substrate made of polymeric material in which there is perfect compatibility between the PO2-N nanoparticles as described above (optionally in combination with at least one further virucidal and/or bactericidal and/or fungicidal agent as previously described) with which the substrate is nanofunctionalised and the polymeric material itself.
- Said compatibility is connected to the amount of PO2- N nanoparticles as described above (optionally in combination with at least one further virucidal and/or bactericidal and/or fungicidal agent as previously described) that can effectively functionalise the substrate and, consequently, the photocatalytic performances thereof.
- Said compatibility makes it possible, in fact, to have a better anchorage of said nanoparticles to the substrate and to be able not only to effectively functionalise the substrate with large amounts of PO2-N nanoparticles as described above (optionally in combination with at least one further virucidal and/or bactericidal and/or fungicidal agent as previously described), but also to maintain the latter effectively adherent thereto, thus ensuring a long-lasting photocatalytic activity with high performances resulting in the effective killing of a virus and/or of fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or of bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudom
- said substrate can be effectively coated with a nanoparticle coating of the aforesaid thickness, which proves to be advantageously compatible and adherent to the underlying polymeric material over an extended period of time.
- said nanofunctionalised substrate is a substrate of polymeric material
- said nanofunctionalised substrate can be obtained/obtainable by means of a process comprising the steps of:
- step (ii) applying, on the at least one inner and/or outer surface of the substrate obtained in step (i), a suspension of PO2-N nanoparticles as previously described, wherein said nanoparticles are preferably present in the suspension ad a concentration comprised between 1 and 30% weight/weight, by means of a technique selected in the group consisting of: “spray coating”, “flow coating”, “dip coating”, “spin coating”, “Meyer bar coating”, “gravure coating”, “knife coating”, “kiss coating”, “die coating” and “film transfer”; with the condition that, if the PO2-N nanoparticles are present within the polymeric material in step (i), step (ii) can optionally be omitted.
- the polymeric material comprising PO2-N nanoparticles used in step (i) is preferably a polymeric nanocomposite material.
- Said polymeric nanocomposite material is preferably obtained by compounding, i.e.
- the nanofunctionalised substrate made of polymeric material preferably in the form of pellets, and subsequently extruding either the nanofunctionalised substrate made of polymeric material or, alternatively, a polymeric nanocomposite thread, which is subsequently processed by means of a 3D printing or injection moulding technique in order to produce the nanofunctionalised substrate made of polymeric material as previously described.
- the substrate is further nanofunctionalised with at least one further virucidal and/or bactericidal and/or fungicidal agent
- said at least one further virucidal and/or bactericidal and/or fungicidal agent selected from among: a source of silver (in the form of a silver salt, e.g. a silver nitrate or sulphate, or silver nanoparticles), manganese oxide (IV) (MnC ) nanoparticles, zinc oxide (ZnO) nanoparticles, a source of copper (in the form of a copper salt, e.g.
- the possibility of being able to functionalise the polymeric material before processing it to produce the nanofunctionalised substrate makes it possible to standardise production so as to obtain different nanofunctionalised substrates comprising the same amount of PO2-N nanoparticles and to use them effectively to kill a virus and/or to kill fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or to kill bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micro
- this embodiment further enables a second functionalisation to be carried out, optionally, by coating the substrate (already nanofunctionalised in step (i) in which the T1O2-N nanoparticles are present within the polymeric material) with a nanoparticle coating through the application of a suspension of T1O2-N nanoparticles, as previously described.
- the substrate prepared according to step (i) can undergo a further treatment adapted to impart further macroroughness.
- Said further treatment is preferably selected in the group consisting of: laser treatment, embossing of the mould, and a combination thereof.
- the mould itself can be designed and constructed so that the desired roughness is formed precisely during the mechanical action of pressing and the subsequent extraction from the mould. This proves particularly advantageous in the event that the substrate is prepared with the injection moulding or extrusion techniques, which impart to the substrate macroroughness values that are generally lower than those required by the present invention.
- the substrate is prepared by means of 3D printing.
- the operation of forming the substrate by means of 3D printing effectively produces a macroroughness which, though in the case of traditional applications it represents a problem, being undesirable, in this case constitutes an advantage, as it makes it possible to effectively increase the compatibility between the polymeric material of the substrate and the T1O2-N nanoparticles and thus to increase the activity of killing said virus and/or said fungi and/or said bacteria performed by the nanofunctionalised substrate according to the present invention.
- the suspension of PO2-N nanoparticles of the above-described step (ii) is as previously described.
- the rheology of said suspension is preferably characterised by a density comprised between 0.6 and 1 g/cm 3 , more preferably between 0.7 and 0.9 g/cm 3 , and by a viscosity comprised between 0.8 and 1.3 mPa-s, more preferably between 0.9 and 1.1 mPa-s, measured at 25 °C.
- the Applicant has nonetheless surprisingly found that, with the same weight of the applied suspension of PO2-N nanoparticles, the amount of nanoparticles effectively adhering to the substrate and, therefore, functionalising the substrate, shows to be considerably higher (preferably comprised between 1 and 5 g/m 2 , preferably between 1.5 and 3 g/m 2 , more preferably between 1.8 and 2,6 g/m 2 ) in the case of the nanofunctionalised substrate as described above, characterised by a nanoroughness, measured by means of an electron microscope, comprised between 10 and 50 nm and a macroroughness, measured by means of an electron microscope, comprised between 100 and 600 pm, wherein said nano- and macroroughness is diffused internally and/or superficially, as compared to a substrate made of the same polymeric material, but having different nanoroughness and macroroughness values.
- the substrate is further nanofunctionalised with at least one further virucidal and/or bactericidal and/or fungicidal agent
- at least one further virucidal and/or bactericidal and/or fungicidal agent selected from among: a source of silver (in the form of a silver salt, e.g. a silver nitrate or sulphate, or silver nanoparticles), manganese oxide (IV) (MnC ) nanoparticles, zinc oxide (ZnO) nanoparticles, a source of copper (in the form of a copper salt, e.g.
- step (ii) is a step of pre-activating the substrate obtained in the previously described step (i) by immersion in an organic solvent, for an immersion time comprised between 0.1 and 50 minutes and a subsequent heat treatment at a temperature comprised between 30 and 60 °C.
- said organic solvent is selected in the group consisting of: acetone, ethyl alcohol, isopropyl alcohol, methyl alcohol and a combination thereof. More preferably, said organic solvent is acetone.
- Said immersion time is preferably comprised between 1 and 10 minutes.
- Said heat treatment is preferably carried out at a temperature comprised between 35 and 55 °C.
- said pre-treatment step (ii’) proves to be effective in further increasing the compatibility between the polymeric material of the substrate and the subsequent nanoparticle coating, thus further increasing the adhesion of said coating to the substrate and consequently improving, over time, the photocatalytic performance thereof and the killing of a virus and/or of fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or of bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacterace
- a further step (iii) can be carried out.
- Said step (iii) is a step of subjecting the substrate obtained to a heat treatment at a temperature comprised between 30 and 90 °C, for a treatment time comprised between 0.5 and 3 hours.
- Said temperature is preferably comprised between 35 and 55 °C.
- Said treatment time is preferably comprised between 0.5 and 2 hours.
- the heat treatment step (iii) makes it possible to assure a further improved adhesion of the nanoparticle coating to the substrate.
- the choice of the material of the substrate according to this preferred embodiment makes it possible not only to obtain, by means of 3D printing, injection moulding or extrusion techniques, a substrate with variable geometries, thicknesses and shapes which can be modulated according to need, but also to adjust the optical properties thereof.
- the nanofunctionalised substrate is translucid or transparent, even more preferably transparent.
- the Applicant has found that modulating the parameters listed above (shape, thickness, geometry, degree of opacity/translucency/transparency of the substrate, degree of roughness imparted to the substrate by the presence of TiC -N nanoparticles comprised within it and/or in the form of a nanoparticle coating) makes it possible to vary and optimise the properties and the performance of the substrate itself, in terms of killing said virus and/or said fungi and/or said bacteria, as it is possible to modulate the time of contact of said virus and/or said fungi and/or said bacteria with the nanofunctionalised substrate, the amount of T1O2-N nanoparticles present in and/or on the substrate and the percentage of luminous radiation that irradiates, possibly passing through the support itself or being diffused thereby.
- the Applicant has found that modulating the nano- and macroroughness values makes it possible to assure an effective adhesion of the nanoparticle coating, which otherwise is generally scarcely compatible with a substrate made of polymeric material and has a tendency to peel and come detached, thus deteriorating, over time, the performance of the substrate in terms of killing said virus and/or said fungi and/or said bacteria.
- said nanofunctionalised substrate is a substrate made of ceramic material, preferably selected in the group consisting of: cordierite, mullite, alumina and a combination thereof
- said nanofunctionalised substrate can be obtained/obtainable by means of the process described in WO2018/207107 of the same Applicant, entirely incorporated herein by reference, which comprises the steps of:
- said steps (1) and (2) correspond to steps a) and b) of the process described in WO2019/211787 of the same Applicant, as previously described.
- step (3) comprises a first sub-step (3a) of applying said suspension comprising said PO2 nanoparticles and said nitrogen doping agent to at least one application surface of the substrate, for example by means of a spraying process, and a second sub-step (3b) of applying a flow of compressed air onto said at least one application surface so as to remove any excess nanoparticle coating that may have been deposited.
- the suspension comprising said PO2 nanoparticles and said nitrogen doping agent also called “doping suspension” by means of dip coating or flow coating processes or applications typical of the ceramic field, such as veil-glazing, screen printing, bell-glazing, air brushing or digital injection.
- the heating cycle of step (4) of subjecting the substrate to a heating cycle is carried out after a period of rest of the substrate itself, by heating it to a temperature between 490 °C and 510 °C.
- the heating cycle also called the calcination step
- the doping of the titanium dioxide with the nitrogen from the nitrogen doping agent takes place and the nitrogen penetrates into the T1O2 nanoparticles, positioning itself in a substitutional position within the PO2 crystalline lattice and/or in an interstitial position, that is, within the PO2 crystalline planes.
- the heating cycle is preferably carried out with a temperature variation coefficient of 50 °C/h for a period of ten hours, reaching a maximum temperature of about 500 °C.
- a 3-hour heating cycle can be implemented, with a preheating step, a 500 °C heating step and a cooling step, with a running speed of about 4 m/h.
- the heating cycle is of a duration substantially ranging from 2 to 11 hours, depending on the type of heating device used.
- the subject matter of the present invention further relates to a device for killing a virus and/or for killing fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or for killing bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micrococcaceae, Mycobacteriaceae, Spirochaetaceae, Leptospiraceae, and a combination thereof; said device comprising at least one nanofunctionalised substrate and at least one light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm, preferably
- the subject matter of the present invention also relates to a device for killing a pathogenic agent; said pathogenic agent preferably being selected from among said virus and/or said fungi and/or said bacteria, as described in the present patent application; said device comprising at least one nanofunctionalised substrate and at least one light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm, preferably between 250 and 600 nm.
- said at least one nanofunctionalised substrate and said at least one light source are arranged in such a way that the radiation emitted by said at least one light source irradiates at least partly, preferably entirely, the nanofunctionalised substrate.
- said device comprises said at least one nanofunctionalised substrate “associated” with said at least one light source.
- said nanofunctionalised substrate is as previously described.
- said nanofunctionalised substrate is “activated” by irradiation with light (i.e. radiation) having a wavelength comprised between 10 and 1500 nm, preferably between 250 and 600 nm, preferably when the device, and hence the at least one light source, are switched on.
- said device is a filtration device that enables the decontamination of a fluid, preferably air and/or water and/or a body fluid, from said virus and/or said fungi and/or said bacteria comprised within said fluid.
- said filtration device further comprises at least one system for ventilation and/or the distribution of a fluid, preferably air and/or water and/or body fluid, configured to allow the passage of said fluid within said filtration device, preferably favouring contact with and/or the passage through the at least one nanofunctionalised substrate.
- said filtration device comprising at least one nanofunctionalised substrate as described above and at least one light source, is characterised in that said at least one nanofunctionalised substrate completely surrounds and/or incorporates said at least one light source, said at least one light source preferably being positioned so as not to obstruct the flow of the fluid, preferably air and/or water and/or body fluid, during its passage within the device.
- said device is a lighting apparatus.
- said lighting apparatus comprises a substrate for one or more lighting elements having inner and/or outer light diffusion surfaces, characterised in that said inner and/or outer surfaces are partly or entirely coated with the PO2-N nanoparticles as previously described (optionally in combination with at least one further virucidal and/or biocidal agent as previously described).
- the at least one nanofunctionalised substrate and the at least one light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm, preferably between 250 and 600 nm, coincide.
- said lighting apparatus can comprise at least one nanofunctionalised substrate as previously described and a support for one or more lighting elements, having inner and/or outer light diffusion surfaces, characterised in that said inner and/or outer surfaces are partly or entirely coated with the PO2-N nanoparticles as previously described (optionally in combination with at least one further virucidal and/or biocidal agent as previously described).
- said device comprise the at least one nanofunctionalised substrate as described above, but the at least one light source is also nanofunctionalised.
- said lighting apparatus as described above can also be integrated with a system for ventilation and/or the distribution of a fluid, preferably air and/or water and/or body fluid, configured to allow the passage of said fluid within said device (i.e. lighting apparatus), preferably favouring contact with and/or the passage through the at least one nanofunctionalised substrate.
- said device can also be defined as a “filtering lighting apparatus”.
- the lighting apparatus as described above can be an LED panel, a projector, a light bulb or a furnishing object, such as, for example a ceiling light fixture, a lamp (fixed or movable) or a chandelier.
- said lighting apparatus comprises a plurality of lighting elements (for example LEDs) organised in a chain-like succession.
- light diffusion shields are present in a position below or above the aforesaid chain of lighting elements.
- said at least one light source is selected from a light source, preferably an LED, with a colour temperature comprised between 3000 and 7000 K, preferably between 3000 and 6000 K, more preferably between 6000 and 7000 K.
- Said at least one light source preferably further has an irradiance comprised between 70 and 100 W/m 2 .
- Said at least one light source preferably further has a yield in terms of luminous flux comprised between 500 and 1000 Im.
- said device therefore has, in addition to a photocatalytic activity for killing said virus and/or said bacteria and/or said fungi, also a virucidal and/or bactericidal and/or fungicidal activity in the absence of irradiation by a source of light (UV light and/or visible light and/or sunlight), that is, for example when at least one light source comprised in the device itself is not in action.
- a source of light UV light and/or visible light and/or sunlight
- the Applicant has found that, given the versatility of the process and the materials used to produce the nanofunctionalised substrate, according to one embodiment, it is possible to advantageously miniaturise said substrate and, consequently, the device that will comprise it, preferably the filtration device. Furthermore, the Applicant has found that, given the possibility of choosing thicknesses and the possibility of varying the geometries of the substrate as described above (for example by creating an internal design of the substrate providing for multiple paths that advantageously make it possible to increase the contact time of said virus and/or said fungi and/or said bacteria present in the fluid to be treated), it is possible to obtain an optimisation of the fluid- dynamic system of the device and obtain an effective killing of said virus and/or said fungi and/or said bacteria.
- the present invention also relates to a method for killing a virus and/or for killing fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or for killing bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micrococcaceae, Mycobacteriaceae, Spirochaetaceae, Leptospiraceae, and a combination thereof; said method comprising the steps of:
- the present invention also relates to a method for killing a pathogenic agent; said pathogenic agent preferably being selected from among said virus and/or said fungi and/or said bacteria, as described in the present patent application; said method comprising the steps of:
- step (B) of “placing” said nitrogen-doped TiC>2 nanoparticles in contact with said virus and/or with said fungi and/or with said bacteria is to be understood as a step in which said virus and/or said fungi and/or said bacteria “enter spontaneously into contact” or “are placed in contact” (for example by an operator/individual and/or by conveying a flow of a fluid comprising said virus and/or said fungi and/or said bacteria over said nanoparticles, etc.) or else “are in contact by chance” with said nanoparticles, so that said nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight can be able to perform their killing activity against said virus and/or said fungi and/or said bacteria.
- step (B) of “placing” said nitrogen-doped TiC>2 nanoparticles in contact with said virus and/or with said fungi and/or with said bacteria
- virus and/or fungi and/or bacteria in contact with said nitrogen-doped PO2 nanoparticles means that said virus and/or said fungi and/or said bacteria are on the surface of said nanoparticles, preferably being adsorbed onto it.
- the source of UV light and/or visible light and/or sunlight of step (C) is a light source as previously described.
- the subject matter of the present invention also relates to a method for killing a virus and/or for killing fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or for killing bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micrococcaceae, Mycobacteriaceae, Spirochaetaceae, Leptospiraceae, and a combination thereof; said method comprising the steps of:
- A providing a substrate nanofunctionalised with nitrogen-doped TiC>2 (Ti02-N) nanoparticles activatable by UV light and/or visible light and/or sunlight;
- the present invention also relates to a method for killing a pathogenic agent; said pathogenic agent preferably being selected from among said virus and/or said fungi and/or said bacteria, as described in the present patent application; said method comprising the steps of:
- A providing a substrate nanofunctionalised with nitrogen-doped TiC>2 (Ti02-N) nanoparticles activatable by UV light and/or visible light and/or sunlight;
- step (C’) of “placing” said nanofunctionalised substrate in contact with said virus and/or with said fungi and/or with said bacteria is to be understood as a step in which said virus and/or said fungi and/or said bacteria “enter spontaneously into contact” or “are placed in contact” (for example by an operator/individual and/or by conveying a flow of a fluid comprising said virus and/or said fungi and/or said bacteria over said nanoparticles, etc.) or else “are in contact by chance” with said substrate nanofunctionalised with nitrogen-doped T1O2 (T1O2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight, so that said nanoparticles can be able to perform their killing activity against said virus and/or said
- virus and/or fungi and/or bacteria in contact with said nanofunctionalised substrate means that said virus and/or said fungi and/or said bacteria are on at least one surface, be it an inner and/or outer surface, of said substrate nanofunctionalised with said nanoparticles, more preferably being adsorbed onto the surface of said nanoparticles.
- the source of UV light and/or visible light and/or sunlight of step (C’) is a light source as previously described.
- the subject matter of the present invention also relates to a method for killing a virus and/or for killing fungi selected in the group consisting of: Cladosporium, Microsporum, Aspergillus, Penicillium, Mucor, Rhizopus, Cryptococcus, Exophiala, Candida, Fusarium, and a combination thereof; and/or for killing bacteria selected in the group consisting of: Streptococcaceae, Bacillaceae, Clostridiaceae, Enterococcaceae, Staphylococcaceae, Pseudomonadaceae, Legionellaceae, Campylobacteraceae, Moraxellaceae, Enterobacteriaceae, Micrococcaceae, Mycobacteriaceae, Spirochaetaceae, Leptospiraceae, and a combination thereof; said method comprising the steps of:
- (A”) providing a device comprising at least one substrate nanofunctionalised with nitrogen-doped TiC>2 nanoparticles and at least one light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm, preferably between 250 and 600 nm;
- the present invention also relates to a method for killing a pathogenic agent; said pathogenic agent preferably being selected from among said virus and/or said fungi and/or said bacteria, as described in the present patent application; said method comprising the steps of:
- (A”) providing a device comprising at least one substrate nanofunctionalised with nitrogen-doped PO2 nanoparticles and at least one light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm, preferably between 250 and 600 nm;
- step (C”) of “placing” said device in contact with said virus and/or with said fungi and/or with said bacteria is to be understood as a step in which said virus and/or said fungi and/or said bacteria “enter spontaneously into contact” or “are placed in contact” (for example by an operator/individual and/or by conveying a flow of a fluid comprising said virus and/or said fungi and/or said bacteria over said nanoparticles, etc.) or else “are in contact by chance” with said device comprising at least one substrate nanofunctionalised with nitrogen-doped PO2 (PO2-N) nanoparticles activatable by UV light and/or visible light and/or sunlight, so that said nanoparticles can be able to perform their killing activity against said virus and/or said fungi and/or said bacteria.
- step (B”) of “placing” said device in contact with said virus and/or with said fungi and/or with said bacteria is to be understood as a step in which said virus and/or said
- virus and/or fungi and/or bacteria in contact with said device means that said virus and/or said fungi and/or said bacteria are on at least one surface, be it an inner and/or outer surface of said at least one substrate nanofunctionalised with said nanoparticles comprised in the device, more preferably being adsorbed onto the surface of said nanoparticles.
- light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm” is to be understood as synonymous with “source of UV light and/or visible light and/or sunlight”.
- the irradiating step (C), (C’) or (C”) is carried out for a period of time comprised between 0.5 and 48 hours, preferably between 1 and 12 hours, more preferably between 2 and 8 hours.
- said virus is selected in the group consisting of: Coronaviridae, preferably Orthocoronavirinae, more preferably alphacroronavirus (alpha-CoV), even more preferably HCoV-229E and HCoV-NL63, betacoronavirus (beta-CoV), even more preferably OC43, HKU1 , SARS-CoV, MERS-CoV, Bovine coronavirus (BCoV) and SARS-CoV-2;
- Bacteriophages preferably Myoviridae, Siphoviridae, Podoviridae, Cystoviridae, Microviridae, more preferably FC174;
- Caliciviridae preferably Norovirus
- Picornaviridae preferably Enterovirus, Echovirus, Rhinovirus and Coxsakievirus, even more preferably Coxsakievirus B, Enterovirus C, even more preferably poliovirus;
- Reoviridae preferably Rotavirus, more preferably Rotavirus A, Rotavirus B, Rotavirus C, Rotavirus D, Rotavirus and, Rotavirus F, Rotavirus G, Rotavirus H, Rotavirus I, Rotavirus J;
- Adenoviridae preferably Adenovirus, more preferably Atadenovirus, Aviadenovirus, lchtadenovirus, Mastadenovirus, Siadenovirus;
- Astroviridae preferably Avastrovirus, more preferably Avastrovirus 1 , Avastrovirus 2, Avastrovirus 3;
- Anelloviridae preferably Alphatorquevirus, more preferably Torque teno virus 1 ;
- Pramixoviridae preferably respiratory syncytial virus (RSV) and parainfluenza virus;
- Poxviridae preferably Orthopoxvirus, more preferably Variola virus;
- Filoviridae preferably Ebolavirus
- Orthomyxoviridae preferably Alphainfluenzavirus, Betainfluenzavirus, Deltainfluenzavirus, Gammainfluenzavirus, influenza virus A, influenza virus B, H 1 N1 and H5N1 ; hepatitis virus, preferably hepatitis virus A (FIAV), hepatitis virus B (FIBV), hepatitis virus C (FICV), hepatitis virus D (FIDV), hepatitis virus E (HEV); and a combination thereof.
- FIAV hepatitis virus A
- FIBV hepatitis virus B
- FICV hepatitis virus C
- FIDV hepatitis virus D
- HEV hepatitis virus E
- said virus is selected in the group consisting of:
- coronavirinae preferably Orthocoronavirinae, more preferably alphacoronavirus (alpha-CoV), even more preferably FICoV-229E and FICoV-NL63, betacoronavirus (beta-CoV), even more preferably OC43, HKU1 , SARS-CoV, MERS-CoV, Bovine coronavirus (BCoV) and SARS-CoV-2;
- Poxviridae preferably Orthopoxvirus, more preferably Variola virus;
- - Filoviridae preferably Ebolavirus
- Orthomyxoviridae preferably Alphainfluenzavirus, Betainfluenzavirus, Deltainfluenzavirus, Gammainfluenzavirus, influenza virus A, influenza virus B, H1 N1 and H5N1 ;
- hepatitis virus preferably hepatitis virus A (HAV), hepatitis virus B (HBV), hepatitis virus C (HCV), hepatitis virus D (HDV), hepatitis virus E (HEV); and a combination thereof.
- HAV hepatitis virus A
- HBV hepatitis virus B
- HCV hepatitis virus C
- HCV hepatitis virus D
- HEV hepatitis virus E
- HAV hepatitis virus A
- HBV hepatitis virus B
- HCV hepatitis virus C
- HDV hepatitis virus D
- HEV hepatitis virus E
- said virus is selected in the group consisting of:
- alpha-CoV alphacoronavirus
- beta-CoV betacoronavirus
- HKU1 SARS-CoV
- MERS-CoV MERS-CoV
- Bovine coronavirus BCoV
- SARS-CoV-2 alphacoronavirus
- Orthopoxvirus preferably Variola virus
- said virus is selected in the group consisting of: HCoV-229E, HCoV-NL63, OC43, HKU1 , SARS-CoV, MERS-CoV, Bovine coronavirus (BCoV) and SARS-CoV-2, preferably SARS-CoV, MERS-CoV, Bovine coronavirus (BCoV) and SARS-CoV-2, even more preferably SARS-CoV, Bovine coronavirus (BCoV) and SARS-CoV-2, even more preferably Bovine coronavirus (BCoV) and SARS-CoV-2.
- said fungi are selected in the group consisting of:
- Cladosporium preferably Cladosporium cladosporioides and Cladosporium herbarum;
- Microsporum preferably Microsporum audouinii, Microsporum felineum, Microsporum ferrugineum and Microsporum minutissimum;
- Aspergillus preferably Aspergillus fumigatus, Aspergillus sydowii and Aspergillus usus;
- Penicillium preferably Penicillium corylophilum, Penicillium chrysogenum, Penicillium glabrum, Peniciullium corylophilum and Penicillium marneffei;
- Mucor preferably Mucor hiemalis
- Rhizopus preferably Rhizopus oryzae and Rhizopus nigricans
- Cryptococcus preferably Cryptococcus neoformans, Cryptococcus laurentii and Cryptococcus albidus;
- Exophiala preferably Exophiala jeanselmei, Exophiala dermatitidis, Exophiala hongkongensis, Exophiala phaeomuriformis, Exophiala pisciphila, Exophiala wasneckii;
- Candida preferably Candida albicans, Candida auris, Candida dubliniensis, Candida glabrata, Candida lusitaniae, Candida parapsilosis and Candida tropicalis;
- Fusarium preferably Fusarium oxysporum; and a combination thereof.
- said fungi are selected in the group consisting of: Cladosporium cladosporioides, Cladosporium herbarum, Microsporum audouinii, Microsporum felineum, Microsporum ferrugineum, Microsporum minutissimum, Aspergillus fumigatus, Aspergillus sydowii, Aspergillus usus, Penicillium corylophilum, Penicillium chrysogenum, Penicillium glabrum, Peniciullium corylophilum, Penicillium marneffei, Mucor hiemalis, Rhizopus oryzae, Rhizopus nigricans, Cryptococcus neoformans, Cryptococcus laurentii, Cryptococcus albidus, Exophiala jeanselmei, Exophiala dermatitidis, Exophiala hongkongensis, Exophiala phaeomuriformis, Exophial
- said bacteria are selected in the group consisting of:
- Streptococcaceae preferably Streptococcus, more preferably Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus faecalis and Streptococcus mutans;
- Bacillus preferably Bacillus, more preferably Bacillus subtilis, Bacillus anthracis, Bacillus oleronius, and Bacillus cereus,
- Clostridiaceae preferably Clostridium, more preferably Clostridium difficile, Clostridium perfringens, Clostridium tetani and Clostridium botulinum;
- Enterococcaceae preferably Enterococcus, more preferably vancomycin- resistant Enterococcus spp. (VRE), Enterococcus faecalis and Enterococcus Faecium;
- VRE vancomycin- resistant Enterococcus spp.
- Staphylococcaceae preferably Staphylococcus, more preferably Staphylococcus auricularis, Staphylococcus capitis, Staphylococcus caprae, Staphylococcus cohnii, Staphylococcus lugdunensis, Staphylococcus saprophyticus,
- Staphylococcus aureus even more preferably methicillin-resistant
- Staphylococcus aureus MRSA
- CNS coagulase-negative staphylococci
- Staphylococcus epidermidis even more preferably Staphylococcus epidermidis
- Pseudomonadaceae preferably Pseudomonas, more preferably Pseudomonas aeruginosa and Pseudomonas fluorescens;
- Legionellaceae preferably Legionella, more preferably Legionella pneumophila
- Campylobacteraceae preferably Arcobacter, preferably Arcobacter butzleri;
- Moraxellaceae preferably Acinetobacter, preferably Acinetobacter Baumannii;
- Enterobacteriaceae preferably Enterobacter, Salmonella, more preferably Salmonella enterica, Klebsiella, more preferably Klebsiella pneumoniae, Klebsiella granulomatis, Shigella, more preferably Shigella dysenteriae and Shigella flexneri, Escherichia, more preferably Escherichia Coli;
- Micrococcaceae preferably Micrococcus, more preferably Micrococcus luteus
- Mycobacteriaceae preferably Mycobacterium, more preferably Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium leprae, Mycobacterium marinum, Mycobacterium paratuberculosis and Mycobacterium ulcerans;
- Treponema preferably Treponema pallidum, Treponema carateum, Treponema per pneumonia and Treponema endemicum;
- Leptospiraceae preferably Leptospira, preferably Leptospira interrogans, Leptospira kirschneri, Leptospira noguchii, Leptospira alexanderi, Leptospira wellii, Leptospira genomospecies 1 , Leptospira borgpetersenii, Leptospira santarosai, Leptospira kmetyi; and a combination thereof.
- said bacteria are selected in the group consisting of: Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus faecalis, Streptococcus mutans, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Clostridium botulinum, Staphylococcus aureus, preferably methicillin- resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS), preferably Staphylococcus epidermidis, Legionella pneumophila, Enterobacter, Salmonella enterica, Klebsiella, preferably Klebsiella pneumoniae and Klebsiella granulomatis, Shigella, preferably Shigella dysenteriae and Shigella flexneri, Escherichia, preferably Escherichia Coli, Mycobacterium tub
- said virus and/or said fungi and/or said bacteria are comprised within a fluid, preferably air and/or water and/or a body fluid, preferably selected from among blood, blood plasma, blood serum, ear wax, faeces, urine, sperm, vaginal secretions, mucus, sebum, sweat, tears, pus, or a combination thereof.
- a fluid preferably air and/or water and/or a body fluid, preferably selected from among blood, blood plasma, blood serum, ear wax, faeces, urine, sperm, vaginal secretions, mucus, sebum, sweat, tears, pus, or a combination thereof.
- said virus and/or said fungi and/or said bacteria are comprised within a current/flow of air, preferably within an aerosol.
- said virus and/or said fungi and/or said bacteria are comprised within a fluid selected from among: a sneeze, breath, a cough or saliva of an individual and/or an animal.
- said virus and/or said fungi and/or said bacteria are present on a surface, preferably adsorbed onto said surface.
- the Applicant has nonetheless found that the use of the nitrogen-doped PO2 nanoparticles activatable by UV light and/or visible light and/or sunlight, or of a substrate nanofunctionalised with said nanoparticles, or of a device comprising said nanofunctionalised substrate and at least one light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm, as described above, according to the present invention, proves to be particularly effective, as it makes it possible to obtain a killing of said virus and/or said fungi and/or said bacteria (when said virus and/or said fungi and/or said bacteria are present either on a surface or in a fluid/aerosol) at a percentage greater than 80%, preferably greater than 95%, more preferably greater than 96%, even more preferably greater than 97%, even more preferably greater than 97.55%, even more preferably greater than 97.99%, even more preferably greater than 98%, even more preferably greater than 98.55%, even more preferably greater than
- the method according to the present invention also proves to be particularly effective, as it makes it possible to obtain a killing of said virus and/or said fungi and/or said bacteria at a percentage greater than 80%, preferably greater than 95%, more preferably greater than 96%, even more preferably greater than 97%, even more preferably greater than 97.55%, even more preferably greater than 97.99%, even more preferably greater than 98%, even more preferably greater than 98.55%, even more preferably greater than 98.99%, even more preferably greater than 99% even more preferably greater than 99.55%, even more preferably greater than 99.99%.
- said killing percentage is greater than 80%, preferably greater than 95%, more preferably greater than 96%, even more preferably greater than 97%, even more preferably greater than 97.55%, even more preferably greater than 97.99%, even more preferably greater than 98%, even more preferably greater than 98.55%, even more preferably greater than 98.99%, even more preferably greater than 99% even more preferably greater than 99.55%, even more preferably greater than 99.99%, after 1 hour, preferably after 4 hours, of activation of said nanoparticles (or of said substrate nanofunctionalised with said nanoparticles) by the UV light and/or visible light and/or sunlight or, in other words, after irradiation of said nanoparticles (or of said substrate nanofunctionalised with said nanoparticles) with a source of UV light and/or visible light and/or sunlight, preferably, with a light source configured to emit radiation having a wavelength comprised between 10 and 1500 nm, preferably between 250 and 600 nm.
- said killing percentage is greater than 99% even more preferably greater than 99.55%, even more preferably greater than 99.99%, after 1 hour, preferably after 4 hours, of activation of said nanoparticles (or of said substrate nanofunctionalised with said nanoparticles) by the UV light and/or visible light and/or sunlight or, in other words, after irradiation of
- the expression “irradiating PO2-N nanoparticles with a source of UV light and/or visible light and/or sunlight” is equivalent to saying that said P02-N nanoparticles, activatable by UV light and/or visible light and/or sunlight, are “activated” and therefore capable of performing their photocatalytic activity, in particular their photocatalytic activity of killing said virus and/or said fungi and/or said bacteria.
- the expression “irradiating a nanofunctionalised substrate with a source of UV light and/or visible light and/or sunlight” is equivalent to saying that said substrate, being nanofunctionalised with said T1O2-N nanoparticles activatable by UV light and/or visible light and/or sunlight, is “activated”, or rather, said nanoparticles that completely or partly coat said substrate and/or are comprised within it, are “activated” and thus capable of performing their photocatalytic activity, in particular their photocatalytic activity of killing said virus and/or said fungi and/or said bacteria.
- EXAMPLE 1 Synthesis of an aqueous suspension comprising T1O2 nanoparticles and a nitrogen doping agent.
- the size of the nanoparticles in the suspension obtained was measured by DLS (Dynamic Light Scattering, Malvern Instruments), and a Zaverage value (which corresponds to the hydrodynamic diameter D z , hence the particle size) equal to 49.9 nm was obtained, with a polydispersity index (Pdl) of 0.221.
- DLS Dynamic Light Scattering, Malvern Instruments
- Pdl polydispersity index
- 100.0 g of the suspension obtained as per example 1 were applied, using the dip coating technique, on a 15x15x2 cm substrate of ceramic material (cordierite) with a honeycomb structure (having a weight of about 336 g).
- Said operation entails the immersion of the substrate in the suspension for about 1 minute; it is then positioned on a grid so that the excess material (i.e. the suspension comprising T1O2 nanoparticles and ammonium citrate dibasic) can be collected and reused.
- the substrate thus prepared was subjected to a firing cycle in a continuous electric oven at 500 °C for 3 hours with the belt speed set on 4 m/h.
- FIGS. 1A and 1 B present SEM images that show a detail of the surface of the nanofunctionalised substrate, i.e. of the substrate coated by T1O2-N nanoparticles, at two different magnifications.
- said T1O2-N nanoparticles coating the substrate have a size of about 50 nm, in accordance with the value of the nanoparticle size determined in the suspension obtained according to Example 1.
- flat rectangular samples with a size of 2x6 cm (12 cm 2 ) were taken from the nanofunctionalised substrate.
- the kill tests were carried out by the certified laboratories of Eurofins Biolab Sri, Vimodrone (Milan), Italy. The tests were carried out using a COOL WFIITE LED with a power of 25 W as the light source for irradiating the substrates.
- the activity of the nanofunctionalised substrate according to the present invention (i.e. obtained as per example 2) in terms of killing Escherichia coli K12DSM11250 was tested according to standard ISO 22196:2011 (Measurement of antibacterial activity on plastics and other non-porous surfaces); the method was duly modified and adapted as reported here.
- test inoculum In the first two hours after the start of the test, a loop of the test bacteria was transferred into 20 ml of the suspension medium (1/500 dilution of TSB in WFI) and evenly dispersed. The suspension was adjusted to a concentration of about 1 - 5 x 10 6 cfu/ml, with a target concentration of 2.5 x 10 6 cells/ml; the concentration was verified with the “pour-plate” method. The viable bacteria were quantified by means of 1 :10 serial dilutions in Tryptone water and plated in duplicate in TSA at 35 °C ⁇ 1 °C for 24-72 hours.
- test inoculum was separately positioned in a sterile Petri dish. 0.1 ml of the test inoculum previously prepared was inoculated onto the surface of the samples. The test inoculum was covered with a square film of about 324 mm 2 , which was delicately pressed to ensure that the test inoculum would spread to the edges of the film, but not go beyond.
- RH relative humidity
- N (100 x C x D x V)/A
- N is the number of viable bacteria recovered per cm 2 per sample
- C is the average number of plates for the duplicated plates
- D is the dilution factor for the counted plates
- V is the volume, in ml, added to each sample
- A is the surface, in mm2, of the covering film.
- R is the antibacterial activity
- Uo is the mean of the Log of the number of viable bacteria recovered at to from the control sample
- Ut is the mean of the Log of the number of viable bacteria, recovered at the contact time t from the control sample
- At is the mean of the Log of the number of viable bacteria, recovered at the contact time t from the nanofunctionalised sample according to the present invention.
- the nanofunctionalised substrate obtained as per example 2 is active against Escherichia coli K12 DSM 11250 and causes a reduction in the bacterial count of Log1.70 and > Log2.34 after 4 and 8 hours of contact (between the substrate and the Escherichia coli), respectively, under the experimental conditions adopted.
- EXAMPLE 4.2 Test of antibacterial activity against Escherichia coli K12 in an aerosol
- the activity of the nanofunctionalised substrate according to the present invention i.e. obtained as per example 2 in terms of killing Escherichia coli K12DSM11250 was also tested in the case of an aerosol of Escherichia coli K12DSM11250.
- the tests were carried out inside an Airlock chamber with a volume of 1 m 3 for a nebulisation time of 30 minutes.
- the tests were carried out in triplicate (Replicate 1 , Replicate 2 and Replicate 3) using a device comprising a nanofunctionalised substrate obtained as per example 3 and a non- nanofunctionalised substrate made of ceramic material (cordierite) with a honeycomb structure as the control sample.
- the surfaces of the test chamber were sanitised with wipes soaked in a 6% H2O2 solution before and after the execution of every test, then dried with sterile wipes after 30 minutes of exposure to the H2O2.
- 6 contact plates were used to check for microbial contamination after the sanitisation treatment. The contact plates were incubated at 30 °C-35 °C for 2 days and then at 20 °C-25 °C for 5 days.
- the results of the microbial test on the test chamber after the sanitisation treatment before and after the execution of every test are shown, by way of example, for Replicate 1 and only for the tests with the device comprising the nanofunctionalised sample, in Tables 4.1 and 4.2.
- the replicates of the experimental tests Replicate 2 and Replicate 3
- Similar results were obtained and in all cases the microbial test was passed.
- the sterilised Collison nebu iser - filled with bacterial suspension - was connected to the test chamber by means of a sterilised glass tube for aerosol delivery, surrounded by a thermostatic water bath in order to obtain a temperature within the aerosol of 20 °C ⁇ 5 °C.
- the Collison nebuliser was connected to the air flow system.
- the test chamber and the content thereof were exposed to the bacterial aerosol for 30 minutes.
- the level of environmental contamination after the opening of the test chamber and sanitisation were monitored during the experimental stage in order to validate the sanitisation procedure using 6 test plates placed outside the test chamber. The plates were incubated at 30 °C-35 °C for 2 days and then at 20-25 °C for 5 days.
- results of the microbial test on the environment outside the test chamber during nebulisation are shown in Table 5.
- results of the microbial test are shown, by way of example, only for Replicate 1 and only for the test with the device comprising the nanofunctionalised sample.
- Replicate 2 and Replicate 3 replicates of the experimental tests
- Replicate 3 replicates of the experimental tests
- control sample similar results were obtained and in all cases the microbial test was passed.
- the device obtained according to Example 3 was positioned inside the test chamber near the nebulisation delivery tube and was switched on (i.e. by turning on the LED light and the ventilation system) for at least one hour before the start of the test. Subsequently, a bacterial suspension of Escherichia coli K12 as described above was nebulised inside the test chamber for 30 minutes. 8 sterile TSA plates were inserted into the test chamber as settling plates and distributed in such a way as to cover the entire base surface. The plates were opened shortly before the chamber was closed in order to sample and record the bacteria touching the bottom surface of the chamber during the exposure time (considering a sufficiently homogeneous exposure of the aerosolised inoculum).
- the nebulisation was stopped and the device was left on for a contact time of 4 hours.
- the 8 settling plates were recovered and incubated for at least 48 hours at 37 °C ⁇ 1 °C in order to measure the contamination by microorganisms.
- the number of CFU/plate (Na) was determined.
- Three experimental tests were carried out (Replicate 1 , Replicate 2 and Replicate 3).
- a control experiment was carried out using a substrate made of ceramic material (cordierite) having a honeycomb structure, but not functionalised and not inserted within a device (Nc), in order to measure the initial microbial contamination inside the test chamber.
- a bacterial suspension of Escherichia coli K12 as described above was nebulised inside the test chamber for 30 minutes.
- 8 sterile TSA plates were inserted into the test chamber as settling plates and distributed in such a way as to cover the entire base surface. The plates were opened shortly before the chamber was closed in order to sample and record the bacteria touching the bottom surface of the chamber during the exposure time (considering a sufficiently homogeneous exposure of the aerosolised inoculum).
- the nebulisation was stopped and the 8 settling plates were recovered and incubated for at least 48 hours at 37 °C ⁇ 1 °C in order to measure the contamination by microorganisms.
- the number of CFU/plate (Nc) as determined.
- the device comprising a substrate nanofunctionalised with PO2-N nanoparticles obtained as per example 3 shows activity against Escherichia coli K12 DSM 11250 and causes a mean reduction of 99.14% in the viability of the microorganism after 4 hours of contact time, following 30 minutes of nebulisation of a suspension containing said microorganism, under the experimental conditions adopted.
- BCoV Bovine coronavirus The viral strain used for the test was BCoV Bovine coronavirus; strain: S379 Riems; cell line: PCT cells (Ovis aries), code CCLV-RIE 11.
- BCoV is a virus used as a surrogate for SARS-related viruses, as it belongs to the same genus, Betacoronavirus 1 , and has shown a susceptibility similar to that of formulations of the World Health Organisation (WHO) in published studies. For this reason, BCoV is considered as a certified reference model for carrying out experimental tests and studying the behaviour of viruses vis-a-vis chemical and physical agents.
- the activity of the nanofunctionalised substrate according to the present invention in terms of killing Bovine Coronavirus was tested according to standard ISO 21702:2019 (Measurement of antibacterial activity on plastics and other non-porous surfaces); the method was duly modified and adapted as reported here.
- the tests were carried out by direct contact of 12 cm 2 (2x6 cm) BCoV flat rectangular samples taken from nanofunctionalised substrates obtained as per example 2 and analogous non-nanofunctionalised substrates (control samples).
- the tests were carried out in triplicate (Replicate 1 , Replicate 2 and Replicate 3), both in the case of the nanofunctionalised substrates (nanofunctionalised samples) and in the case of the control samples (non-functionalised).
- Test on the cytotoxicity of the sample examined the sample under examination was not cytotoxic, that is, its contribution in terms of CPE was not visible in the test.
- Assay of virus infectivity virus titration: the minimum titre of the starting viral suspension was sufficiently high to allow at least a theoretical reduction in virus infectivity of 4 LogTCID5o.
- Test on viral infectivity functionalised substrate and control: the amount of infective particles recovered immediately after inoculation from the non-functionalised samples (control) was comprised between 5 and 6LogTCID5o; the amount of infective particles recovered from every non-functionalised sample (control) after 24 hours of contact was not greater than 3LogTCID5o.
- the substrate nanofunctionalised with T1O2-N nanoparticles obtained as per example 2 shows activity against BCoV and causes a complete reduction (i.e. >99.9%) in the viral load after a contact time of 4 hours under the experimental conditions adopted.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Catalysts (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102020000017995A IT202000017995A1 (en) | 2020-07-24 | 2020-07-24 | NANOPARTICLES, NANOFUNCTIONALISED SUBSTRATE AND DEVICE WITH ANTIVIRAL PHOTOCATALYTIC ACTIVITY |
IT102020000018004A IT202000018004A1 (en) | 2020-07-24 | 2020-07-24 | NANOPARTICLES, NANOFUNCTIONALISED SUBSTRATE AND DEVICE WITH ANTIBACTERIAL PHOTOCATALYTIC ACTIVITY |
IT102020000018007A IT202000018007A1 (en) | 2020-07-24 | 2020-07-24 | NANOPARTICLES, NANOFUNCTIONALISED SUBSTRATE AND DEVICE WITH ANTIFUNGAL PHOTOCATALYTIC ACTIVITY |
PCT/IB2021/056631 WO2022018678A1 (en) | 2020-07-24 | 2021-07-22 | Nanoparticles, nanofunctionalised substrate and device with antiviral and/or antibacterial and/or antifungal photocatalytic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4185340A1 true EP4185340A1 (en) | 2023-05-31 |
Family
ID=77367450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21755821.2A Pending EP4185340A1 (en) | 2020-07-24 | 2021-07-22 | Nanoparticles, nanofunctionalised substrate and device with antiviral and/or antibacterial and/or antifungal photocatalytic activity |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4185340A1 (en) |
WO (1) | WO2022018678A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116199921B (en) * | 2023-03-11 | 2024-04-19 | 华中农业大学 | Chitosan composite film, composite film liquid and fresh-keeping application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3097835A1 (en) * | 2018-05-02 | 2019-11-07 | Colorobbia Consulting S.R.L. | Nitrogen-doped tio2 nanoparticles and the use thereof in photocatalysis |
CN110946147A (en) * | 2019-12-18 | 2020-04-03 | 连云港永荣生物科技有限公司 | Safe and environment-friendly sewage disinfection powder and preparation method and application thereof |
-
2021
- 2021-07-22 WO PCT/IB2021/056631 patent/WO2022018678A1/en active Application Filing
- 2021-07-22 EP EP21755821.2A patent/EP4185340A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022018678A1 (en) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kumaravel et al. | Antimicrobial TiO2 nanocomposite coatings for surfaces, dental and orthopaedic implants | |
Chen et al. | Synergistic antibacterial mechanism and coating application of copper/titanium dioxide nanoparticles | |
Daoud et al. | Surface functionalization of cellulose fibers with titanium dioxide nanoparticles and their combined bactericidal activities | |
Tallósy et al. | Investigation of the antibacterial effects of silver-modified TiO 2 and ZnO plasmonic photocatalysts embedded in polymer thin films | |
WO2009051817A1 (en) | Photocatalytic titanium dioxide nanocrystals | |
US9642358B2 (en) | Antimicrobial lighting system | |
Martínez-Montelongo et al. | Development of a sustainable photocatalytic process for air purification. | |
US9724440B2 (en) | Environmental cleaning and antimicrobial lighting component and fixture | |
US20140119985A1 (en) | Photodynamic Control of Microbial Growth on Surfaces | |
Sousa et al. | Photoinactivation of various antibiotic resistant strains of Escherichia coli using a paint coat | |
Ismail et al. | Self-cleaning application of mesoporous ZnO, TiO2 and Fe2O3 films with the accommodation of silver nanoparticles for antibacterial activity | |
US10434203B2 (en) | Reduction of infections in healthcare settings using photocatalytic compositions | |
De Jong et al. | Pre–post evaluation of effects of a titanium dioxide coating on environmental contamination of an intensive care unit: the TITANIC study | |
EP4185340A1 (en) | Nanoparticles, nanofunctionalised substrate and device with antiviral and/or antibacterial and/or antifungal photocatalytic activity | |
Belgroune et al. | Bacterial inactivation on sputtered TiOMoN and TiOMoN-Ag thin films under solar simulated light | |
CN111683692A (en) | Photocatalysis method for disinfecting inner wall surface and composition of washable bactericidal paint with photocatalysis performance | |
EP3491078A1 (en) | Contaminant-activated photocatalysis | |
Ramsden | Can bacteria develop resistance to photocatalytically generated reactive oxygen species | |
ES2928009B2 (en) | Photocatalytic coating with antimicrobial properties | |
IT202000018004A1 (en) | NANOPARTICLES, NANOFUNCTIONALISED SUBSTRATE AND DEVICE WITH ANTIBACTERIAL PHOTOCATALYTIC ACTIVITY | |
IT202000018007A1 (en) | NANOPARTICLES, NANOFUNCTIONALISED SUBSTRATE AND DEVICE WITH ANTIFUNGAL PHOTOCATALYTIC ACTIVITY | |
IT202000017995A1 (en) | NANOPARTICLES, NANOFUNCTIONALISED SUBSTRATE AND DEVICE WITH ANTIVIRAL PHOTOCATALYTIC ACTIVITY | |
Chang et al. | Photocatalytic Bactericidal effect of Ag/TiO2 nano-thin film on nosocomial infections control | |
Mili et al. | Advances in nanoarchitectonics of antimicrobial tiles and a quest for anti-SARS-CoV-2 tiles | |
WO2016099508A1 (en) | An antimicrobial lighting system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230215 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230601 |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240219 |